Brief report Special Issues

A CAP for Healthy LivingMainstreaming Health into the EU Common Agricultural Policy
European Public Health Alliance (EPHA), 2015

  • Received: 24 November 2015 Accepted: 25 November 2015 Published: 18 December 2015
  • Citation: Nikolai Pushkarev. A CAP for Healthy LivingMainstreaming Health into the EU Common Agricultural PolicyEuropean Public Health Alliance (EPHA), 2015[J]. AIMS Public Health, 2015, 2(4): 844-887. doi: 10.3934/publichealth.2015.4.844

    Related Papers:

    [1] Salman Safdar, Calistus N. Ngonghala, Abba B. Gumel . Mathematical assessment of the role of waning and boosting immunity against the BA.1 Omicron variant in the United States. Mathematical Biosciences and Engineering, 2023, 20(1): 179-212. doi: 10.3934/mbe.2023009
    [2] Yukihiko Nakata, Ryosuke Omori . The change of susceptibility following infection can induce failure to predict outbreak potential by $\mathcal{R}_{0}$. Mathematical Biosciences and Engineering, 2019, 16(2): 813-830. doi: 10.3934/mbe.2019038
    [3] Xi-Chao Duan, Xue-Zhi Li, Maia Martcheva . Dynamics of an age-structured heroin transmission model with vaccination and treatment. Mathematical Biosciences and Engineering, 2019, 16(1): 397-420. doi: 10.3934/mbe.2019019
    [4] Kento Okuwa, Hisashi Inaba, Toshikazu Kuniya . Mathematical analysis for an age-structured SIRS epidemic model. Mathematical Biosciences and Engineering, 2019, 16(5): 6071-6102. doi: 10.3934/mbe.2019304
    [5] Mostafa Adimy, Abdennasser Chekroun, Claudia Pio Ferreira . Global dynamics of a differential-difference system: a case of Kermack-McKendrick SIR model with age-structured protection phase. Mathematical Biosciences and Engineering, 2020, 17(2): 1329-1354. doi: 10.3934/mbe.2020067
    [6] Desmond Z. Lai, Julia R. Gog . Waning immunity can drive repeated waves of infections. Mathematical Biosciences and Engineering, 2024, 21(2): 1979-2003. doi: 10.3934/mbe.2024088
    [7] Lili Liu, Xi Wang, Yazhi Li . Mathematical analysis and optimal control of an epidemic model with vaccination and different infectivity. Mathematical Biosciences and Engineering, 2023, 20(12): 20914-20938. doi: 10.3934/mbe.2023925
    [8] Sarafa A. Iyaniwura, Rabiu Musa, Jude D. Kong . A generalized distributed delay model of COVID-19: An endemic model with immunity waning. Mathematical Biosciences and Engineering, 2023, 20(3): 5379-5412. doi: 10.3934/mbe.2023249
    [9] Simone De Reggi, Francesca Scarabel, Rossana Vermiglio . Approximating reproduction numbers: a general numerical method for age-structured models. Mathematical Biosciences and Engineering, 2024, 21(4): 5360-5393. doi: 10.3934/mbe.2024236
    [10] Junyuan Yang, Rui Xu, Xiaofeng Luo . Dynamical analysis of an age-structured multi-group SIVS epidemic model. Mathematical Biosciences and Engineering, 2019, 16(2): 636-666. doi: 10.3934/mbe.2019031


  • The dynamics of immune status among host individuals plays a crucial role in the spread of infectious diseases. Individuals which have just recovered from disease obtain any immunity, however, its level of effectiveness is not necessarily time-constant but can vary as time evolves. An individual's immunity may decay as time goes by, while it could be regained by boosting, which means the immunity enhancement by continued or intermittent exposure to infectious agent.

    The boosting and waning dynamics of immune status and its epidemiological consequences have been studied by many authors. Historically speaking, it should be firstly noted that Kermack and McKendrick [2] had already developed a class-age structured epidemic model allowing reinfection of recovered individuals from the 1930s. Reinfection of recovered individuals can be seen as a consequence of waning immunity, and it can cause a backward bifurcation of endemic steady state ([3,4]). If the loss of immunity of recovered individuals implies the direct reversion from the recovered class to the susceptible class, the basic system is formulated as the well-known SIRS model, which has been long studied in mathematical epidemiology. For example, Bhattacharya and Adler [5] developed a recovery-age dependent SIRS model to show that loss of immunity could produce oscillations. On the other hand, Nakata, et al. [6] considered an infection-age structured SIRS model to examine global stability conditions for an endemic equilibrium. Okuwa, et al. [7] studied a chronological age-structured SIRS model to establish its endemic threshold results.

    It is more challenging to consider synergistic consequences of boosting and waning of immunity. Heffernan and Keeling [8] discussed how vaccination can have a range of unexpected consequences as it reduces the natural boosting of immunity as well as reducing the number of naive susceptibles. Kababi{\'r}e, et al. [9] examined a model for a vector-borne disease with immunity decay and immunity boosting of human hosts. Leung, et al. [10] studied how immune boosting and cross immunity can influence the timing and severity of epidemics. It was also shown that the epidemiological patterns of an infectious disease may change considerably when the duration of vaccine-acquired immunity differs from that of infection-acquired immunity [11]. Dafilis, et al. [12] showed that allows for boosting of immunity may naturally give rise to undamped oscillatory behavior for biologically realistic parameter choices. Diekmann, et al. [13] developed a mathematical model to describe the distribution of immune status shaped by continuous waning and occasional boosting. Epidemiological consequences of waning of vaccine-derived immunity are also discussed in [14], which topic should be paid more attention in the context of COVID-19.

    In a series of papers from the 1980s, Aron ([15,16,17]) developed mathematical models for malaria to consider the effect of immunity boosting by reinfection, and discussed that the boosting mechanism may explain the age-specific prevalence of acute malaria and the functional relationship between the rate of reversion from the immune class to the susceptible class and the force of infection at the endemic steady state, although those pioneering works have been so far almost neglected. In those models, the host population are divided into three classes: susceptibles (uninfected individuals); infecteds (the individuals with severe and symptomatic infection); immunes (the individuals with mild, subclinical, or asymptomatic infection). The recovered individuals are assumed to be partially susceptible and infective, and their immune status can be boosted by reinfection. Since subclinical individuals are assumed to become completely susceptible again with a recovery-age dependent reversion rate, so the Aron model can be seen as an extension of the well-known SIRS epidemic model.

    In [4], Inaba showed that the Aron model can be more generally formulated as an age-structured SIRS model, where asymptomatic infecteds are distributed by the recovery-age (or immunity clock), that is, time elapsed since the moment of recovery from the symptomatic infectious class. In Inaba's formulation, the boosting effect is expressed by a boundary condition such that the immunity clock is reset to zero by boosting (reinfection). Under this formulation, the functional relationship between the reversion rate and the force of infection is then naturally induced, and Aron's result is obtained as a special case in which the probability density function for the loss of immunity is given by a delta function. If the immunity level is waning monotonically as time evolves, it is inversely proportional to recovery-age, that is, the reset of the immunity clock means the boosting of immunity.

    By using the immunity clock mechanism, we could consider the dynamics of continuous change of individual immune status in the spread of infectious diseases, which is more advantageous and natural than the traditional compartment model formulation. For another kind of structured boosting models, the reader may refer to [18], [19] and [20], where immune individuals are structured by a general immunity level parameter. Although the immunity clock mechanism may be more restrictive than the general immunity level parameter dynamics, the clock mechanism is theoretically much more tractable.

    For the Aron–Inaba formulation, a crucial assumption is that newly boosted individuals have the same immunity level as individuals who have just recovered from symptomatic infection, but it would be a restrictive assumption in order to consider the incomplete boosting. Therefore, in this paper, we extend the Aron–Inaba model so that the effect of boosting is that the immunity clock can be reset to any time less than the recovery-age at which reinfection occurs. If the immunity level is monotone decreasing with respect to the recovery-age, our assumption implies that newly boosted (reinfected) individuals could get, with a given probability, any level of immunity less than the maximum level that is gained by recovery from symptomatic infection status.

    In the following, we first give the well-posedness result of our basic system. Next, we investigate the initial invasion condition which is formulated by the local stability of disease-free steady state. Thirdly we consider the existence of endemic steady states. Finally, we provide a bifurcation analysis of endemic steady states. Based on Lyapunov–Schmidt type arguments, we determine the direction of bifurcation that endemic steady states bifurcate from the disease-free steady state when the basic reproduction number passes through the unity. We give a necessary and sufficient condition for backward bifurcation to occur.

    We consider a closed population with the constant total size $ N $ divided into three parts: susceptibles, clinical (symptomatic) infectives and subclinical (asymptomatic) infectives. The subclinical class is structured by variable $ \tau $, called the recovery-age, which is the time elapsed since the recovery from clinical infectious class. Let $ S(t) $ and $ I(t) $ be the size of susceptible and clinical infectives at time $ t $, respectively, and let $ r(t, \tau) $ be the age density function of subclinical infectious class. By extending the Aron–Inaba model [4], we formulate the following age-structured epidemic model:

    $ dS(t)dt=μNμS(t)λ(t)S(t)+0γ(τ)r(t,τ)dτ,dI(t)dt=λ(t)S(t)(μ+q)I(t),r(t,τ)t+r(t,τ)τ=(λ(t)+μ+γ(τ))r(t,τ)+λ(t)τp(τ,σ)r(t,σ)dσ,r(t,0)=qI(t)+λ(t)0p(0,σ)r(t,σ)dσ,
    $
    (2.1)

    where $ \mu > 0 $ is the natural death rate, $ q > 0 $ is the recovery rate from clinical infection, $ \gamma(\tau) $ is the reversion rate at recovery-age $ \tau $. The force of infection $ \lambda $ is given by

    $ λ(t)=1N(β1I(t)+0β2(τ)r(t,τ)dτ),
    $
    (2.2)

    where $ \beta_1 $ and $ \beta_2(\tau) $ are transmission coefficients reflecting the infectivity for clinical individual and subclinical individual at recovery-age $ \tau $, respectively. For simplicity, we assume that the same force of infection $ \lambda $ is applied to both susceptibles and subclinical individuals.

    As a technical but biologically reasonable assumption, we suppose that $ \gamma $, $ \beta_2 \in L^\infty (0, \infty) $ and denote their upper bound as $ \gamma^\infty $ and $ \beta_2^\infty $, respectively. Moreover, we also define the survival function $ \Gamma $ induced from the reversion rate $ \gamma $ as follows:

    $ Γ(τ):=exp(τ0γ(z)dz)
    $
    (2.3)

    The parameter $ p(\tau, \sigma) $ is a key to formulate our novel idea, which means the proportion that subclinical individuals with recovery-age $ \sigma $ reset their recovery-age to $ \tau < \sigma $ when their immunity is boosted by reinfection. Then we assume the following condition:

    $ p(0,σ)+σ0p(τ,σ)dτ=1,σ>0,
    $
    (2.4)

    so that the number of subclinical population conserves through the boosting, that is,

    $ \int_{0}^{\infty} r(t,\sigma)d\sigma = \int_{0}^{\infty} \int_\tau^\infty p(\tau,\sigma)r(t,\sigma)d\sigma d\tau+\int_{0}^{\infty} p(0,\sigma)r(t,\sigma)d\sigma, $

    holds. Furthermore, we assume $ p^\infty: = \sup_{\tau < \sigma}p(\tau, \sigma) < \infty $. For instance, following types of function satisfy the condition (2.4):

    1. $ p(\tau, \sigma) = e^{-(\sigma-\tau)} $.

    2.

    $ p(τ,σ)={2πs2exp((στ)22s2),τ>0,12πs2σ0exp(η22s2)dη,τ=0,
    $
    (2.5)

    where $ s > 0 $ is a given constant.

    3. $ p(\tau, \sigma) = \frac{1}{1+\sigma} $.

    4. $ p(0, \sigma) = 0 $ and $ p(\cdot, \sigma) $ is an arbitrary probability density function whose support is $ [0, \sigma] $.

    Note that the original Aron model corresponds to the special case that $ p(0, \sigma) = 1 $ and $ p(\tau, \sigma) = 0 $ for all $ \tau > 0 $ ([4], chapter 8). As is mentioned above, if the immunity level is monotone decreasing with respect to recovery-age, our assumption implies that, by through the reset of recovery-age, the immunity level of reinfected individuals could be boosted to any level of immunity less than the highest immunity level gained by recovery from the clinical status. Finally it is easily checked that

    $ N=S(t)+I(t)+0r(t,τ)dτ,
    $
    (2.6)

    is constant for all $ t\geq 0 $, since we assume there is no disease-induced death rate.

    As a preliminary study for our basic system (2.1), we here consider the linearized system at the diesease-free steady state $ (S, I, r) = (N, 0, 0) $. Let $ (Y, z(\cdot)) $ be the perturbation of the infected population densities $ (I, r) $ from the equilibrium state $ (0, 0) $. Then the linearized system at the disease-free steady state is described as follows:

    $ dY(t)dt=λ(t)N(μ+q)Y(t),z(t,τ)t+z(t,τ)τ=(μ+γ(τ))z(t,τ),z(t,0)=qY(t),λ(t)=1N(β1Y(t)+0β2(τ)z(t,τ)dτ),
    $
    (2.7)

    which is already introduced in [4], because the boosting effect is the second order effect, so the parameter $ p $ does not appear in (2.7), and the effect of immunity boosting can be neglected as long as we consider the initial invasion phase.

    Let us introduce the renewal equation for the density of newly infecteds denoted by $ v(t): = N\lambda(t) $. The linearized equation for clinically infected population density in (2.7) implies

    $ Y(t)=e(μ+q)tY(0)+t0e(μ+q)(ts)λ(s)Nds.
    $
    (2.8)

    Integrating the second equation in (2.7) along the characteristic line, we obtain

    $ z(t,τ)={qY(tτ)eμτΓ(τ),tτ>0,z(0,τt)Γ(τ)Γ(τt)eμτ,tτ<0.
    $
    (2.9)

    Then we obtain the following integral equation:

    $ v(t)=β1Y(t)+0β2(τ)z(t,τ)dτ=g(t)+β1t0e(μ+q)(ts)v(s)ds+t0β2(τ)qeμτΓ(τ)tτ0e(μ+q)(tτs)v(s)dsdτ,
    $
    (2.10)

    where the initial data is given by

    $ g(t): = \beta_1 e^{-(\mu+q)t}Y(0)+\int_0^t \beta_2 (\tau) q e^{-\mu \tau}\Gamma(\tau) e^{-(\mu+q)(t-\tau)} Y(0)d\tau + \int_t^\infty q\beta_2(\tau) \frac{\Gamma(\tau)}{\Gamma(\tau-t)}e^{-\mu t} z(0,\tau-t)d\tau. $

    Changing the order of integrals, we have the following renewal equation:

    $ v(t)=g(t)+t0Φ(s)v(ts)ds,
    $
    (2.11)

    where the net reproduction kernel $ \Phi $ is defined as

    $ Φ(s):=β1e(μ+q)s+s0β2(τ)qeμτΓ(τ)e(μ+q)(sτ)dτ.
    $
    (2.12)

    Then the basic reproduction number $ R_0 $ is given by

    $ R0=0Φ(s)ds=β1μ+q+qμ+q0β2(τ)eμτΓ(τ)dτ,
    $
    (2.13)

    which is the expected number of secondary cases produced by an infected individual during its entire period of infectiousness in a completely susceptible population.

    Note that the basic reproduction number is traditionally defined as the spectral radius of the next generation operator ([4,21,22]). Since the density of newly infecteds in the initial invasion phase is described by the renewal integral equation as (2.11), its next generation operator is given by

    $ K:=0Φ(s)ds,
    $
    (2.14)

    which is acting on the state space of infected individuals. In our case, $ K $ is a scalar, so $ K $ itself gives $ R_0 $.

    From the epidemiological threshold principle, we can expect that if $ R_0 > 1 $, the disease can invade into the host population, while it cannot if $ R_0 < 1 $. We will give a mathematical justification for this invasion principle for our system in section 4.

    Here we prove the existence, uniqueness and positivity of solution semiflow of the system (2.1). If $ I $ and $ r(\cdot) $ are once determined, $ S $ is given by the relation (2.6). So it is sufficient to consider the $ (I, r) $-system as follows:

    $ dI(t)dt=λ(t)(NI(t)0r(t,τ)dτ)(μ+q)I(t),r(t,τ)t+r(t,τ)τ=(λ(t)+μ+γ(τ))r(t,τ)+λ(t)τp(τ,σ)r(t,σ)dσ,r(t,0)=qI(t)+λ(t)0p(0,σ)r(t,σ)dσ,
    $
    (3.1)

    where the state space of $ (I, r) $ is given by $ \left\{(I, r) \in \mathbb R_+ \times L^1_+(\mathbb R_+): I+\|r\|_{L^1} \le N\right\} $.

    In order to formulate the basic system (3.1) as a semilinear abstract Cauchy problem ([23,24,25]). Let us define the extended state space $ Z $ as $ Z = \mathbb R \times \mathbb R \times L^1(0, \infty) $ and its closed subspace $ Z_0 = \{ 0 \} \times \mathbb R \times L^1(0, \infty) $, where the first element corresponds to the boundary value of $ r $, and the second and third parts give the states of $ I $ and $ r $.

    Let $ A $ be a differential operator on $ X: = \mathbb R \times L^1(\mathbb R_+) $ such as

    $ (Aψ)(τ)=(μψ1(μ+γ(τ))ψ2ddτψ2(τ)) for ψ=(ψ1ψ2())D(A):=R×W1,1(R),
    $
    (3.2)

    and define the linear operator $ \mathcal A $ acting on $ Z $ such that

    $ A(0ψ)=(ψ2(0)Aψ) for (0ψ)D(A):={0}×D(A).
    $
    (3.3)

    Next define the nonlinear operator $ \mathcal F: Z_0 \to Z $ as

    $ F(0ψ)=(qψ1+λ[ψ]0p(0,η)ψ2(η)dη(λ[ψ](Nψ1ψ2L1)qψ1λ[ψ]ψ2(τ)+λ[ψ]τp(τ,η)ψ2(η)dη)),
    $
    (3.4)

    where $ \lambda[\cdot]: \mathbb R_+ \times L^1(\mathbb R_+) \to \mathbb R_+ $ is a functional defined as

    $ λ[ψ]=1N(β1ψ1+0β2(τ)ψ2(τ)dτ).
    $
    (3.5)

    Then it is easy to see that $ \mathcal F $ is a Lipschitz continuous nonlinear perturbation, that is, there is a number $ L > 0 $ such that $ \|\mathcal Fu-\mathcal Fv\|_Z \le L\|u-v\|_Z $ for all $ u, v \in Z_0 $.

    Now formally the system (3.1) can be written as a semilinear abstract Cauchy problem in $ Z $:

    $ du(t)dt=Au(t)+F(u(t)),u(0)=(0u0)Z0.
    $
    (3.6)

    From biological meaning, we are interested in the solution semiflow in $ C_0 \subset Z_0 $, where

    $ C0:={(0(ψ1ψ2()))Z0+:|ψ1|+ψ2L1N}.
    $
    (3.7)

    Then $ \mathcal A $ is not densely defined in $ Z $, but its domain is dense in $ Z_0 $, that is, $ \overline{D(\mathcal A)} = Z_0 $. Moreover, we can observe that $ \mathcal A $ is a resolvent positive, Hille-Yosida type operator as follows:

    Lemma 1. 1. $ \{ \zeta\in\mathbb C \mid \Re \zeta > -\mu \}\subset\rho(A) $.

    2. For $ \zeta > -\mu $, the Hille-Yosida estimation holds as

    $ (ζA)1B(Z)1ζ+μ
    $
    (3.8)

    3. For $ \zeta > 0 $, it holds that $ \zeta(\zeta-\mathcal A)^{-1}(C)\subset C_0 $.

    Proof. Let $ \Re \zeta > -\mu $. Consider the following resolvent equation

    $ (\zeta-\mathcal A)v = u,\quad v = \begin{pmatrix}         0\\         \begin{pmatrix}         v_1\\         v_2(\cdot)\\         \end{pmatrix}
    \\ \end{pmatrix}\in D(\mathcal A), u = \begin{pmatrix}         u_3\\         \begin{pmatrix}         u_1\\         u_2(\cdot)\\         \end{pmatrix}
    \\ \end{pmatrix}\in Z. $

    Then $ v_2(0) = u_3 $, $ \zeta v_1+\mu v_1 = u_1 $ and $ \zeta v_2(\tau)+(\mu+\gamma(\tau))v_2(\tau)+v_2^\prime (\tau) = u_2 (\tau) $ hold. These imply

    $ (\zeta-\mathcal A)^{-1}u = \begin{pmatrix}         0\\         \begin{pmatrix}         \frac{u_1}{\zeta+\mu}\\         u_3e^{-(\zeta+\mu)\tau}\Gamma(\tau)+\int_0^\tau u_2(\sigma) e^{-(\zeta+\mu)(\tau-\sigma)}\frac{\Gamma(\tau)}{\Gamma(\sigma)}d\sigma\\         \end{pmatrix}
    \\ \end{pmatrix}. $

    Hence for $ \zeta > -\mu $ and $ u\in Z $

    $ \| (\zeta-\mathcal A)^{-1} u \|_Z \leq \frac{|u_1|}{\zeta+\mu}+\frac{|u_3|}{\zeta+\mu}+ \int_0^\infty \int_0^\tau |u_2(\sigma)|e^{-(\zeta+\mu)(\tau-\sigma)}d\sigma = \frac{\| u \|_Z}{\zeta+\mu}. $

    From the above, it is obvious that $ \zeta(\zeta-\mathcal A)^{-1}(C)\subset C_0 $ for given $ \zeta > 0 $.

    Subsequently we can observe the quasi-positivity of the nonlinear perturbation term $ \mathcal F $:

    Lemma 2. For sufficiently small $ \epsilon > 0 $, $ (I+\epsilon \mathcal F)(C_0)\subset C $.

    Proof. Let $ \psi = \begin{pmatrix} 0\\         \begin{pmatrix}             \psi_1\\             \psi_2(\cdot)         \end{pmatrix}

    \end{pmatrix} \in C_0, $ then we have

    $ (I+\epsilon\mathcal F) (0ψ)
    = \begin{pmatrix}     \epsilon( q\psi_1+\lambda[\psi] \int_0^\infty p(0,\eta)\psi_2(\eta)d\eta )\\     \begin{pmatrix}         (1-\epsilon q)\psi_1+\epsilon\lambda[\psi](N-\psi_1-\| {\psi_2} \|_{L^1}) \\         (1-\epsilon\lambda[\psi])\psi_2(\tau)+\epsilon\lambda[\psi]\int_\tau^\infty p(\tau,\eta)\psi_2(\eta)d\eta     \end{pmatrix}
    \end{pmatrix}. $

    Since the estimation

    $ \lambda[\psi] \leq \frac{\max\{\beta_1, \beta_2^\infty\}}{N} \| \psi \| \leq \max\{\beta_1, \beta_2^\infty\}, $

    holds for $ \psi\in C_0 $, if we take $ \epsilon > 0 $ such as

    $ 0 < \epsilon < \min\left\{\frac{1}{\max\{\beta_1, \beta_2^\infty\}},\frac{1}{q}\right\} = :\epsilon_0, $

    then $ (I+\epsilon\mathcal F)(C_0)\subset Z_+ $. Suppose $ 0 < \epsilon < \epsilon_0 $. Due to the positivity of each element, we obtain

    $ (I+ϵF)(0ψ)Z=ψ1+ψ2+ϵλ[ψ](Nψ1ψ2L1)=(ψ1+ψ2)(1ϵλ[ψ])+ϵλ[ψ]N,
    $

    where the condition (2.4) is used. Moreover, since $ 1-\epsilon \lambda [\psi] > 1-\frac{\lambda [\psi]}{ \max\{\beta_1, \beta_2^\infty\} }\geq 0 $, the following estimation holds:

    $ \left\| (I+\epsilon\mathcal F) (0ψ)
    \right\|_Z \leq N(1-\epsilon \lambda [\psi])+\epsilon \lambda [\psi]N = N, $

    which implies $ (I+\epsilon \mathcal F)(C_0)\subset C $.

    In order to construct a semiflow in $ C_0 $, we rewrite (3.6) as follows:

    $ ddtu(t)=(A1ϵ)u(t)+1ϵ(I+ϵF)u(t),u(0)C0,
    $
    (3.9)

    where $ \epsilon $ is a small positive number such that $ I+\epsilon \mathcal F $ maps $ C_0 $ into $ C $. Hence it is expected that the solution semiflow of (3.9) could be obtained by a positive iteration for the variation of constants formula, but the operator $ \mathcal A $ has a non-dense domain in $ Z $, $ \mathcal A-1/\epsilon $ is not an infinitesimal generator of a strongly continuous semigroup. Thus we seek a solution in a weak sense.

    For a given $ T > 0 $, $ u: [0, T) \to C_0 $ is an integral solution of (3.9) if $ u $ is continuous on $ [0, T) $ and it satisfies

    $ t0u(s)dsD(A),t[0,T),
    $
    (3.10)

    and

    $ u(t)=u(0)+(A1ϵ)t0u(s)ds+1ϵt0(I+ϵF)u(s)ds,t[0,T).
    $
    (3.11)

    Note that (3.10) implies that $ u(t) \in Z_0 = \overline{D(\mathcal A)} $ and the integral solution becomes the classical solution if and only if $ u $ is differentiable on $ (0, T) $ [26].

    Let $ \mathcal A_0 $ be the part of $ \mathcal A $ in $ Z_0 $, that is,

    $ A0=A on D(A0)={(0ψ)D(A):A(0ψ)Z0}.
    $
    (3.12)

    Then the following holds:

    Lemma 3. $ \overline{D(\mathcal A_0)} = Z_0 $ holds and $ \mathcal A_0 $ generates a strongly continuous semigroup $ \{ \mathcal T_0 (t) \}_{t\geq 0} $ on $ Z_0 $ and $ \mathcal T_0(t) C_0 \subset C_0 $ for all $ t > 0 $.

    Proof. It follows from definition that $ (0ψ)

    \in D(\mathcal A_0) $ if and only if $ \psi \in D(A) $ with $ \psi_2(0) = 0 $. Then we have $ \overline{D(\mathcal A_0)} = Z_0 $. Define a differential operator $ A_0 $ such that

    $ (A0ψ)(τ)=(μψ1(μ+γ(τ))ψ2ddτψ2(τ)),
    $
    (3.13)

    where

    $ \psi = (ψ1ψ2)
    \in D(A_0): = \{\psi \in D(A): \psi_2(0) = 0\}. $

    Then $ A_0 $ is a generator of $ C_0 $-semigroup $ T_0(t) $, $ t \ge 0 $ on $ \mathbb R \times L^1(\mathbb R_+) $ such that

    $ T0(t)ψ=(ψ1eμtU(t)ψ2),
    $
    (3.14)

    where $ U(t) $, $ t \ge 0 $ denotes the translation semigroup on $ L^1 $ defined by

    $ (U(t)ϕ)(τ):={0,tτ>0ϕ(τt)eμtΓ(τ)Γ(τt),τt>0,ϕL1(R+),
    $
    (3.15)

    and we have $ D(\mathcal A_0) = \{0\} \times D(A_0) $. Thus $ \mathcal A_0 $ is densely defined on $ Z_0 $ and it generates a $ C_0 $-semigroup on $ Z_0 $ such that

    $ T0(t)(0ψ)=(0T0(t)ψ),
    $
    (3.16)

    Since the semiflow $ T_0(t) $, $ t > 0 $ makes a closed subset $ \{\psi = (\psi_1, \psi_2) \in \mathbb R_+ \times L^1_+(\mathbb R_+): |\psi_1|+\|\psi_2\|_{L^1} \le N\} $ positively invariant, we have for $ t > 0 $, $ (\mathcal T_0 (t)) (C_0)\subset C_0 $.

    Proposition 1. For a given $ T > 0 $ and $ u(0) \in C_0 $, a positive function $ u \in C(0, T; C_0) $ is an integral solution for $(3.9)$ if and only if it is the positive continuous solution of the extended variation of constants formula on $ C_0 $ as

    $ u(t)=e1ϵtT0(t)u(0)+limζ1ϵt0e1ϵ(ts)T0(ts)ζ(ζ(A1ϵ))1(I+ϵF)u(s)ds.
    $
    (3.17)

    Proof. First we assume that $ u \in C(0, T; C_0) $ is an integral solution of (3.9). Applying the resolvent operator $ \zeta(\zeta-(\mathcal A-\frac{1}{\epsilon}))^{-1} $ with $ \zeta > 0 $ to the both sides of (3.9), we obtain

    $ uζ(t)=uζ(0)+ζ(ζ(A1ϵ))1(A1ϵ)t0u(s)ds+ζ(ζ(A1ϵ))11ϵt0(I+ϵF)u(s)ds,
    $
    (3.18)

    where $ u_\zeta(t): = \zeta(\zeta-(\mathcal A-\frac{1}{\epsilon}))^{-1}u(t) $. Then it is easily seen that $ u_\zeta \in D(\mathcal A_0) \cap C_0 $. Since $ \zeta(\zeta-(\mathcal A-\frac{1}{\epsilon}))^{-1}(\mathcal A-\frac{1}{\epsilon}) $ is bounded, it follows that

    $ ζ(ζ(A1ϵ))1(A1ϵ)t0u(s)ds=t0ζ(ζ(A1ϵ))1(A1ϵ)u(s)ds=t0(A01ϵ)ζ(ζ(A1ϵ))1u(s)ds=t0(A01ϵ)uζ(s)ds.
    $

    On the other hand, due to the continuity of $ (I+\epsilon \mathcal F)u(t) $, integral and the resolvent operator can be interchanged in the third part of the right hand side in (3.18). Therefore we arrive at the following equation on $ D(\mathcal A_0) \cap C_0 $:

    $ uζ(t)=uζ(0)+t0(A01ϵ)uζ(s)ds+1ϵt0ζ(ζ(A1ϵ))1(I+ϵF)u(s)ds.
    $
    (3.19)

    Then it follows that $ u_\zeta $ is a classical solution of the Cauchy problem on $ Z_0 $ as

    $ ddtuζ(t)=(A01ϵ)uζ(s)+1ϵζ(ζ(A1ϵ))1(I+ϵF)u(t),uζ(0)=ζ(ζ(A1ϵ))1u(0).
    $
    (3.20)

    Applying the standard variation of constants formula to (3.19), we have

    $ u(t)=e1ϵtT0(t)u(0)+1ϵt0e1ϵ(ts)T0(ts)ζ(ζ(A1ϵ))1(I+ϵF)u(s)ds.
    $
    (3.21)

    Therefore, it follows from $ \lim_{\zeta \to \infty} u_\zeta = u $ that we have (3.17). Conversely, we assume that $ u(t) $ is the positive continuous solution of (3.17). Consider a linear inhomogeneous Cauchy problem on $ Z $ as:

    $ ddtv(t)=(A1ϵ)v(t)+1ϵ(I+ϵF)u(t),v(0)=u(0).
    $
    (3.22)

    Since the generator $ \mathcal A-\frac{1}{\epsilon} $ satisfies the Hille–Yosida estimate, it follows from Da Prato–Sinestrari theorem [27] that (3.22) has a unique integral solution $ v(t) \in Z $ such that

    $ v(t)=u(0)+(A1ϵ)t0v(s)ds+1ϵt0(I+ϵF)v(s)ds,t[0,T).
    $
    (3.23)

    Applying the same argument as above, we obtain the extended variation of constants formula again as:

    $ v(t)=e1ϵtT0(t)u(0)+limζ1ϵt0e1ϵ(ts)T0(ts)ζ(ζ(A1ϵ))1(I+ϵF)u(s)ds,
    $
    (3.24)

    which shows that $ u(t) = v(t) $ for all $ t \in [0, T) $. Then the positive continuous solution of (3.17) is the integral solution of the basic system (3.9).

    From the above arguments, we obtain the well-posedness result for the basic system (3.6) as follows:

    Proposition 2. The basic model $(3.6)$ has a unique, global, positive integral solution.

    Proof. From the above observation, it is sufficient to show that the extended variation of constants formula (3.17) has a unique continuous solution for some $ T > 0 $. Define an operator $ \mathcal H $ on $ C(0, T;C_0) $ by

    $ (Hu)(t):=e1ϵtT0(t)u(0)+limζ1ϵt0e1ϵ(ts)T0(ts)ζ(ζ(A1ϵ))1(I+ϵF)u(s)ds.
    $
    (3.25)

    Since the right hand side of (3.25) is a linear convex combination of elements in $ C_0 $, so $ \mathcal H $ maps $ C_0 $ into itself. Therefore, using the local Lipschitz continuity of the bounded perturbation $ \mathcal F $ and the contraction mapping principle to $ \mathcal H $, we can find a small $ T > 0 $ such that a positive local solution for the extended variation of constants formula (3.17) uniquely exists. Moreover, it follows from the fact $ \|\mathcal T_0(t)\| \le 1 $ and $ \|\zeta (\zeta-(\mathcal A-\frac{1}{\epsilon}))^{-1}\| \le 1 $ that

    $ \|(\mathcal H u)(t)\|_Z \le \|u(0)\|_Z+\frac{1}{\epsilon}\|I+\epsilon \mathcal F\|\int_{0}^{t}\|u(s)\|_Zds. $

    Hence we know that the fixed point of $ \mathcal H $ grows at most exponentially as time evolves, so the local solution can be extended to a global solution.

    From the above argument, we know that for each $ u(0) \in C_0 $, (3.9) has a unique integral solution $ u: \mathbb R_+ \to C_0 $, then $ \mathcal T(t)u(0) = u(t) $ defines the nonlinear semigroup $ \mathcal T(t) $, $ t \ge 0 $ on $ C_0 $. Here we consider the stability of steady states of $ \mathcal T(t) $, $ t \ge 0 $, which are time-independent solutions of (3.11)

    Here we examine the initial invasion phase of epidemic, that is, we consider the local stability of the disease-free equilibrium $ u = 0 $ of $ \mathcal T(t) $, $ t \ge 0 $. Since $ \mathcal F $ is continuously F\'rechet differentiable at a steady state $ u = u^* $, the nonlinear semigroup $ \mathcal T(t) $, $ t \ge 0 $ is also Fréchet differentiable at $ u = u^* $ and its derivative at $ u = u^* $ is the strongly continuous linear semigroup $ \mathcal S(t) $, $ t \ge 0 $ generated by the part of $ \mathcal B: = \mathcal A+\mathcal F'[u^*] $ in $ Z_0 $. Let $ \mathcal B_0 $ be the part of $ \mathcal B $ in $ Z_0 $. Then the growth bound $ \omega_0(\mathcal B) $ and the essential growth bound $ \omega_1(\mathcal B) $ are defined as

    $ ω0(B0)=limtt1log(S(t)),ω1(B0)=limtt1log(α[S(t)]),
    $
    (4.1)

    if these exist, where $ \alpha[A] $ is the measure of noncompactness of an operator $ A $. Let $ s(\mathcal B_0): = \sup_{\zeta\in\sigma(\mathcal B_0)} \Re \zeta $ be the spectral bound of $ \mathcal B_0 $. Then the following holds ([28,29]):

    $ ω0(B0)=max{ω1(B0),s(B0)}.
    $
    (4.2)

    If $ \omega_0(\mathcal B_0) < 0 $, we can conclude that the steady state $ u = u^* $ is locally asymptotically stable, in the sense that for $ \omega \in (\omega_0(\mathcal B_0), 0) $ there exists $ \delta > 0 $ such that $ \|\mathcal T(t)u-u^*\|_Z \le e^{\omega t}\|u-u^*\|_Z $ for all $ u \in C_0 $ with $ \|u-u^* \|_Z \le \delta $. On the other hand, $ u^* $ is unstable if at least one eigenvalue of $ \mathcal B_0 $ has strictly positive real part (Theorem 4.2, Corollary 4.3 in [25]).

    Here let us consider the stability of the disease-free steady state for (3.6). The linearized system of (3.6) at $ u = 0 $ is given as follows:

    $ ddtu(t)=(A+DF[0])u(t),
    $
    (4.3)

    where the Fréchet derivative of $ \mathcal F $ at $ 0\in Z $ is denoted by $ D\mathcal F[0] $ and is calculated as

    $ DF[0](0ψ)=(qψ1(λ[ψ]Nqψ10)).
    $
    (4.4)

    Since the range of $ D\mathcal F[0] $ is finite, it is a compact operator. In the following we investigate the spectrum of the part $ \mathcal B_0 $ of the linearized operator $ \mathcal B = \mathcal A+D\mathcal F[0] $.

    Lemma 4. Let $ P_\sigma(\mathcal B_0) $ be the point spectrum of $ \mathcal B_0 $ and let $ \Sigma: = \{z \in \mathbb C: \Re z > -\mu\} $. Then it follows that $ \sigma(\mathcal B_0) \cap \Sigma = P_\sigma(\mathcal B_0) \cap \Sigma $.

    Proof. Consider the resolvent equation

    $ (\zeta-\mathcal B_0)v = u,\quad v = \begin{pmatrix}         0\\         \begin{pmatrix}         v_1\\         v_2(\cdot)\\         \end{pmatrix}
    \\ \end{pmatrix}\in D(\mathcal A), \; u = \begin{pmatrix}         0\\         \begin{pmatrix}         u_1\\         u_2(\cdot)\\         \end{pmatrix}
    \\ \end{pmatrix}\in Z_0. $

    Then we have

    $ v2(0)=qv1,(ζ+μ+q)v1=u1+λ[v]N,ddτv2(τ)=(ζ+μ+γ(τ))v2(τ)+u2(τ).
    $

    Solving the above ODE, we have

    $ v2(τ)=qv1e(ζ+μ)τΓ(τ)+τ0u2(σ)e(ζ+μ)(τσ)Γ(τ)Γ(σ)dσ.
    $
    (4.5)

    Moreover, formally we can calculate $ v_1 $ as

    $ v1=1(ζ+μ+q)(1Δ(ζ))[u1+0β2(τ)τ0u2(σ)e(ζ+μ)(τσ)Γ(τ)Γ(σ)dσdτ],
    $
    (4.6)

    where

    $ Δ(ζ)=1ζ+μ+q[β1+q0β2(τ)e(ζ+μ)τΓ(τ)dτ].
    $
    (4.7)

    Inserting the expression of (4.6) into (4.5), $ v_2 $ can be expressed by $ u_1 $, $ u_2 $, so we can formally calculate $ (\zeta-\mathcal B_0)^{-1}u $. It is clear that $ (\zeta-\mathcal B_0)^{-1}u \in D(\mathcal A) $ if $ u \in Z_0 $ and $ \Re \zeta > -\mu $ and $ \Delta(\zeta)\neq 1 $, so $ \{ \zeta\in\mathbb C: \Delta(\zeta) \neq 1, \Re\zeta > -\mu \} \subset \rho(\mathcal B_0) $. Then we have $ \Omega: = \{ \zeta\in\mathbb C : \Delta(\zeta) = 1, \Re \zeta > -\mu \} \supset \sigma(\mathcal B_0) \cap \Sigma $. On the other hand, if $ \zeta \in \Omega $, we can calculate an eigenfunction for $ \mathcal B_0 $ associated with $ \zeta $ as $ (0, v_1, qv_1 e^{-(\mu+\zeta)\tau}\Gamma(\tau)) $ where $ v_1 $ is any nonzero constant, so we have $ \zeta \in P_\sigma(\mathcal B_0) $. Thus we have $ P_\sigma(\mathcal B_0) \cap \Sigma \supset \Omega \supset \sigma(\mathcal B_0) \cap \Sigma $, but trivially it follows that $ P_\sigma(\mathcal B_0) \cap \Sigma \subset \sigma(\mathcal B_0) \cap \Sigma $, hence we obtain $ \sigma(\mathcal B_0) \cap \Sigma = \Omega = P_\sigma(\mathcal B_0) \cap \Sigma $.

    Lemma 5. If $ \Delta(-\mu) \ge 1 $, $ \Omega = \{ \zeta\in\mathbb C : \Delta(\zeta) = 1, \Re \zeta > -\mu \} $ has a dominant real normal eigenvalue $ \zeta_0 $ and it follows that $ {\rm sign}(\zeta_0) = {\rm sign}(\Delta(0)-1) $.

    Proof. Since $ \zeta \mapsto \Delta(\zeta) $ is an analytic function in $ \Sigma $, each $ \zeta \in \Omega $ is a normal eigenvalue. $ \Delta(\zeta) $ is monotone decreasing from $ \Delta(-\mu) $ to zero as $ \zeta $ moves from $ -\mu $ to $ \infty $. Then there is a unique real root $ \zeta_0 \in [-\mu, \infty) $ of $ \Delta(\zeta) = 1 $ if $ \Delta(-\mu) \ge 1 $, and it follows that $ {\rm sign}(\zeta_0) = {\rm sign}(\Delta(0)-1) $. In this case, $ \zeta_0 $ is the dominant eigenvalue, that is, $ \Re \zeta < \zeta_0 $ for any $ \zeta \in \Omega \setminus \{\zeta_0\} $. In fact, if $ \zeta \in \Omega $ with $ \Re \zeta \le \zeta_0 $ and $ \Im \zeta \neq 0 $, we have $ \Delta(\zeta_0) = 1 = |\Delta(\zeta)| < \Delta(\Re \zeta) $ holds, so $ \Re \zeta < \zeta_0 $ is obtained because of the monotonicity of $ \Delta $ on $ \mathbb R $.

    Proposition 3. If $ R_0 > 1 $, then the disease-free steady state is unstable, while if $ R_0 < 1 $, then it is locally asymptotically stable.

    Proof. It follows from (3.16) that $ \omega_1(\mathcal A_0) \le -\mu $ and $ D\mathcal F[0] $ is a compact perturbation, we have $ \omega_1((\mathcal A + D\mathcal F [0])_0) = \omega_1(\mathcal A_0) \leq -\mu $ ([28,30]). Therefore, $ {\rm sign}(\omega_0(\mathcal B_0)) = {\rm sign}(s(\mathcal B_0)) $. From the above Lemma 5, we know that $ s(\mathcal B_0) < 0 $ if $ \Delta(0) < 1 \le \Delta(-\mu) $. If $ \Delta(-\mu) < 1 $, there is no eigenvalue in $ \Sigma $ because $ |\Delta(\zeta)| \le \Delta(\Re \zeta) \le \Delta(-\mu) < 1 $, so we have $ s(\mathcal B_0) < 0 $ if $ \Delta(0) < 1 $. On the other hand, if $ \Delta(0) > 1 $, it follows from Lemma 5 that there exists a dominant positive eigenvalue. Thus we can conclude that the disease-free steady state is unstable if $ \Delta(0) > 1 $, while if $ \Delta(0) < 1 $, it is locally asymptotically stable. Finally we notice that $ \Delta(0) = R_0 $.

    Let $ (S^*, I^*, r^*(\cdot)) $ be a steady state. Then we have

    $ 0=μNμSλS+0γ(τ)r(τ)dτ,0=λS(μ+q)I,dr(τ)dτ=(μ+λ+γ(τ))r(τ)+λτp(τ,σ)r(σ)dσ,r(0)=qI+λ0p(0,σ)r(σ)dσ,
    $
    (5.1)
    $ λ=1N(β1I+0β2(τ)r(τ)dτ).
    $
    (5.2)

    It is easy to see that $ S^* $ and $ I^* $ are expressed by $ \lambda^* $ and $ r^* $ as follows:

    $ S=1μ+λ(μN+0γ(τ)r(τ)dτ),I=λμ+q1μ+λ(μN+0γ(τ)r(τ)dτ).
    $
    (5.3)

    Solving the equation of $ r^* $ in (5.1), we obtain

    $ r(τ)=e(μ+λ)τΓ(τ)r(0)+τ0σλp(σ,ζ)r(ζ)dζe(μ+λ)(τσ)Γ(τ)Γ(σ)dσ.
    $
    (5.4)

    Substituting the above expression into the boundary condition of $ r^* $, it follows that

    $ r(0)=qI+r(0)0p(0,η)L(0,η;λ)dη+0η0σλp(σ,ζ)r(ζ)dζp(0,η)L(σ,η;λ)dσdη,
    $
    (5.5)

    where for $ \sigma < \eta $, we define

    $ L(\sigma,\eta ;\lambda^*): = \lambda^* e^{-(\mu+\lambda^*)(\eta-\sigma)}\frac{\Gamma(\eta)}{\Gamma(\sigma)}. $

    Then $ p(\zeta, \eta)L(\sigma, \eta; \lambda^*) $ gives the probability density that asymptomatic individuals with recovery-age $ \sigma $ survive to the age of $ \eta $ and then returns to recovery-age $ \zeta $. Since $ \int_\sigma^\infty p(0, \eta)L(\sigma, \eta; \lambda^*)d\eta < 1 $, we have

    $ r(0)=qI+0η0σλp(σ,ζ)r(ζ)dζp(0,η)L(σ,η;λ)dσdη10p(0,η)L(0,η;λ)dη.
    $
    (5.6)

    Then we obtain an integral equation with respect to $ r^* $ as

    $ r(τ)=qIe(μ+λ)τΓ(τ)10p(0,η)L(0,η;λ)dη+e(μ+λ)τΓ(τ)0η0σλp(σ,ζ)r(ζ)dζp(0,η)L(σ,η;λ)dσdη10p(0,η)L(0,η;λ)dη+τ0σp(σ,ζ)r(ζ)dζL(σ,τ;λ)dσ,
    $
    (5.7)

    which can be expressed as follows:

    $ r(τ)=f(τ;λ)+τ0σp(σ,ζ)r(ζ)dζL(σ,τ;λ)dσ+0r(ζ)K1(τ,ζ;λ)dζ,
    $
    (5.8)

    where

    $ g(τ;λ):=e(μ+λ)τΓ(τ)10p(0,η)L(0,η;λ)dη,f(τ;λ):=qλμ+qμNμ+λg(τ;λ),K1(τ,ζ;λ):=g(τ;λ)(1μ+λqλμ+qγ(ζ)+ζ0σλp(σ,ζ)p(0,η)L(σ,η;λ)dηdσ).
    $

    The integral equation (5.8) can be seen as the abstract equation with respect to $ u \in X_+: = L^1_+(\mathbb R_+) $:

    $ u=fλ+Vλu+Fλu,
    $
    (5.9)

    where $ f_{\lambda^*}(\tau) = f(\tau; \lambda^*) $, $ V_{\lambda^*} $ and $ F_{\lambda^*} $ are bounded linear operators from $ X_+ $ into itself given by

    $ (Vλu)(τ):=τ0σp(σ,η)u(η)dηL(σ,τ;λ)dσ,(Fλu)(τ):=0u(ζ)K1(τ,ζ;λ)dζ.
    $

    Since $ V_{\lambda^*} $ is a Volterra operator, its spectral radius is zero, so the positive operator $ (I-V_{\lambda^*})^{-1} $ exists. Thus the equation (5.9) is rewritten as

    $ u=(IVλ)1fλ+(IVλ)1Fλu.
    $
    (5.10)

    Since the operator $ ((I-V_{\lambda^*})^{-1}F_{\lambda^*}) $ is a Volterra operator again, the solution of (5.10) is obtained by the iteration:

    $ u=k=0((IVλ)1Fλ)k(IVλ)1fλ.
    $
    (5.11)

    Substituting the expression (5.11) into (5.2), we obtain the following one-dimensional equation with respect to unknown $ \lambda^* $:

    $ 1=1N(β1μ+q1μ+λ(μN+0γ(τ)r(τ)dτ)+0β2(τ)r(τ)λdτ)=β1μ+qμμ+λ+1N0(β1μ+qλμ+λγ(τ)+β2(τ))r(τ)λdτ,
    $
    (5.12)

    where

    $ r^*(\tau) = \sum\limits_{k = 0}^\infty ((I-V_{\lambda^*})^{-1}F_{\lambda^*})^k (I-V_{\lambda^*})^{-1} f_{\lambda^*}. $

    From the above characteristic equation, the following statement is obtained.

    Proposition 4. If $ R_0 > 1 $, then there exists at least one endemic steady state.

    Proof. Let $ H(\lambda^*) $ be the right hand side of (5.12). First, we prove $ H(0) = R_0 $. For this purpose the value of $ \frac{r^*(\tau)}{\lambda^*} $ at $ \lambda^* = 0 $ needs to be calculated. Since the operator $ F_0 $ is a zero operator, all of the terms for $ k\geq 1 $ in (5.11) are zero. Then we obtain

    $ \left. \frac{r^*(\tau)}{\lambda^*} \right|_{\lambda^* = 0} = \left. \frac{f_{\lambda^*}(\tau)}{\lambda^*} \right|_{\lambda^* = 0} = \frac{qN}{\mu+q}e^{-\mu \tau} \Gamma(\tau), $

    from which it follows that $ H(0) = R_0 $. Next we prove $ \lim_{\lambda^*\rightarrow \infty}H(\lambda^*) = 0 $. First, observe that

    $ H(\lambda^*) \le \frac{\beta_1}{\mu+q}\frac{\mu}{\mu+\lambda^*}+\frac{1}{N} \left( \frac{\beta_1}{\mu+q}\gamma^\infty+\beta_2^\infty \right) \int_0^\infty \frac{r^*(\tau)}{\lambda^*}d\tau. $

    By using the equality obtained by dividing (5.9) by $ \lambda^* $ the following representation follows:

    $ 0r(τ)λdτ=0[fλ(τ)λ+Vλr(τ)λ+Fλr(τ)λ]dτ,
    $
    (5.13)

    where each integral of the right hand side of (5.13) can be estimated as follows:

    $ 0fλ(τ)λdτqμ+qμNμ+λ0e(μ+λ)τΓ(τ)10p(0,η)L(0,η;λ)dηqμ+qμNμ+λμ+λμ0e(μ+λ)τdτ=qN(μ+q)(μ+λ),
    $
    $ 0Vλu(τ)λdτ0τ0σp(σ,η)u(η)dηe(μ+λ)(τσ)dσdτ=0σp(σ,η)u(η)dησe(μ+λ)(τσ)dτdσ=1μ+λ0η0p(σ,η)dσu(η)dηNμ+λ,
    $
    $ 0Fλu(τ)λdτμ+λμ0e(μ+λ)τ1μ+λqμ+qγ(τ)dτ+μ+λμ0τ0σp(σ,τ)p(0,η)e(μ+λ)(ησ)dηdσdτqγμ(μ+q)(μ+λ)+μ+λμ0e(μ+λ)τσp(σ,τ)σe(μ+λ)(ησ)dηdτdσ1μ(μ+λ)(qγμ+q+1).
    $

    Then $ \lim_{\lambda^*\rightarrow \infty} H(\lambda^*) = 0 $ holds. From the above, because of the continuity of $ H $, it turns out that the equation $ 1 = H(\lambda^*) $ has at least one positive solution if $ R_0 > 1 $.

    As is seen in the next section, in our basic model (2.1), $ R_0 < 1 $ does not necessarily imply non-existence of endemic steady states. However, we can formulate a sufficient condition for the global stability of the disease-free steady state implying the non-existence of endemic steady states. Let us define a time-dependent reproduction number $ R_e(t) $ at time $ t $ as

    $ Re(t):=S(t)(μ+q)N(β1I(t)+0β2(τ)r(t,τ)dτ),
    $
    (5.14)

    which is a kind of the effective reproduction number, because it is defined in a partially immunized host population. For the use and the definition of effective reproduction number, the reader may consult [4].

    From the above definition, we have

    $ dI(t)dt=(μ+q)(Re(t)1)I(t).
    $
    (5.15)

    Then we can expect that the disease will be eradicated if the effective reproduction number $ R_e(t) $ is suppressed below the unity and it holds that

    $ 0(Re(x)1)dx=,
    $
    (5.16)

    which is a criteria for disease prevention.

    Proposition 5. Suppose that $(5.16)$ holds. Then the disease-free steady state is globally asymptotically stable, that is, there is no endemic steady state.

    Proof. It follows from (5.15) that

    $ I(t) = I(0)\exp\left((\mu+q)\int_{0}^{t}(R_e(x)-1)dx\right), $

    from which we know that (5.16) implies that $ \lim_{t \to \infty}I(t) = 0 $. Next let $ U(t): = \int_{0}^{\infty}r(t, \tau)d\tau $. Observe that

    $ \frac{dU(t)}{dt} = qI(t)-\mu U(t)-\int_{0}^{\infty}\gamma(\tau)r(t,\tau)d\tau \le qI(t)-\mu U(t). $

    Then we have

    $ U(t) \le U(0)e^{-\mu t}+\int_{0}^{t}e^{-\mu(t-\tau)}qI(\tau)d\tau, $

    which implies that $ \lim_{t \to \infty}U(t) = 0 $. Then $ (S(t), I(t), r(t, \tau)) $ converges to $ (N, 0, 0) $ as $ t \to \infty $, so the disease-free steady state is globally asymptotically stable.

    Corollary 1. If

    $ βN4(μ+q)<1,
    $
    (5.17)

    then the disease-free steady state is globally asymptotically stable.

    Proof. Observe that

    $ R_e(t) = \frac{S(t)}{(\mu+q)N}\left( \beta_1 I(t)+ \int_0^\infty \beta_2(\tau)r(t,\tau)d\tau \right) \le \frac{\beta^\infty}{(\mu+q)N}S(t)(N-S(t)), $

    where we know that $ S(N-S) \le N^2/4 $. If (5.17) holds, we obtain

    $ R_e(t)-1 < \frac{\beta^\infty N}{4(\mu+q)} -1 < 0, $

    which implies (5.16).

    We here consider the bifurcation problem of endemic steady states from the disease-free steady state when the basic reproduction number $ R_0 $ crosses the unity. Especially, the direction of bifurcation is biologically important because in the case of backward bifurcation, there exist multiple endemic steady states even when $ R_0 < 1 $, so $ R_0 < 1 $ is not a sufficient condition to eradicate the disease, whereas if forward bifurcation occurs at $ R_0 = 1 $ and there exists no endemic steady state for $ R_0 < 1 $, lowering $ R_0 $ less than unity becomes the almighty policy for disease eradication. Moreover, we can conclude from the Factorization Theorem [31] that the forwardly bifurcated solution is locally asymptotically stable, while the backwardly bifurcated solution is unstable as long as $ |R_0-1| $ is small enough.

    First, according to [1], we apply the Lyapunov-Schmidt type arguments to the one-parameter bifurcation model. Let us consider the nonlinear operator $ \mathcal G \colon Z_0 \times \mathbb R \rightarrow Z $ with a parameter $ \bar{\beta} $ defined as

    $ G(u,ˉβ)(τ)=(u2(0)+qu1+λ[u;ˉβ]0p(0,σ)u2(σ)dσλ[u;ˉβ](Nu1u2L1)(μ+q)u1u2(τ)(λ[u;ˉβ]+μ+γ(τ))u2(τ)+λ[u;ˉβ]τp(τ,σ)u2(σ)dσ)
    $
    (6.1)

    for $ u = {}^T(0, u_1, u_2(\cdot))\in Z_0 $, where

    $ λ[u;ˉβ]:=ˉβN(β10u1+0β20(τ)u2(τ)dτ),
    $
    (6.2)

    where $ \beta_{10} $ and $ \beta_{20} $ are normalized transmission coefficients such that

    $ β10μ+q+qμ+q0β20(τ)eμτΓ(τ)dτ=1.
    $
    (6.3)

    Then it follows that $ \bar{\beta} = R_0 $ under the above assumption.

    Then the system (2.1) is rewritten as the following abstract differential equation:

    $ dudt=G(u,ˉβ).
    $
    (6.4)

    This equation has a trivial equilibrium $ 0\in Z_0 $, which corresponds to the disease-free steady state. Let $ D_u \mathcal G [u, \bar{\beta}] $ and $ D^2_{uu} \mathcal G [u, \bar{\beta}] $ be the first and second order derivative of $ \mathcal G $ with respect to $ u $, respectively. Similarly, let $ D^2_{u \bar{\beta}} \mathcal G [u, \bar{\beta}] $ be the second order derivative of $ \mathcal G $ with respect to $ u $ and $ \bar{\beta} $. Note that $ D_u \mathcal G [u, \bar{\beta}] $ is a linear map, while $ D^2_{uu} \mathcal G [u, \bar{\beta}] $ and $ D^2_{u \bar{\beta}} \mathcal G [u, \bar{\beta}] $ are bilinear maps. In order to study the direction of the bifurcation, we apply the following theorem:

    Theorem 1 ([1]). Suppose that the following conditions hold:

    $ A1 $ Let $ \mathcal L = D_u \mathcal G [0, 1] $ be the linearization around the zero equilibrium, evaluated at a critical value of parameter $ \bar{\beta} = 1 $, such that $ \mathcal L $ is a closed operator with a simple isolated eigenvalue zero and remaining eigenvalues having negative real part. Let $ \hat v_0 $ be the unique (up to a constant) positive solution of $ \mathcal L \xi = 0 $.

    $ A2 \; \mathcal G(u, \bar{\beta})\in C^2(U_0\times I_0, Z) $ for some neighborhood $ U_0 \times I_0 $ of $ (0, 1) $.

    $ A3 $ Let $ Z^* $ be the dual of $ Z $ and $ \langle \cdot, \cdot \rangle $ be the duality pairing between $ Z $ and $ Z^* $. Assume $ \hat v_0^* \in Z^* $ is the unique (up to a constant) positive vector satisfying $ \langle \mathcal L u, \hat v_0^* \rangle = 0 $, $ \forall u \in Z_0 $, that is, $ \dim(\ker \mathcal L^*) = 1 $, where $ \mathcal L^* $ is the adjoint of $ \mathcal L $, and $ \ker \mathcal L^* = {\rm span}\{\hat v_0^*\} $.

    $ A4 \; \langle D^2_{u \bar{\beta}} \mathcal G[0, 1](\hat v_0, 1), \hat v_0^* \rangle \neq 0 $.

    Then, the direction of the bifurcation is determined by the numbers

    $ a=D2uuG[0,1](ˆv0,ˆv0),ˆv0,b=D2uˉβG[0,1](ˆv0,1),ˆv0.
    $
    (6.5)

    If $ b > 0 $, the bifurcation is backward if and only if $ a > 0 $ and forward if only if $ a < 0 $.

    For our system, the derivatives of the nonlinear mapping $ \mathcal G $ are calculated as the following:

    $ (D_u \mathcal G [0, \bar{\beta}]\xi)(\tau) = (ξ2(0)+qξ1λ[ξ;ˉβ]N(μ+q)ξ1ξ2(τ)(μ+γ(τ))ξ2(τ))
    , $
    $ (D^2_{u \bar{\beta}} \mathcal G [0, \bar{\beta}]\xi)(\tau) = (0λ[ξ;ˉβ]N0)
    , $
    $ (D^2_{uu} \mathcal G [0, \bar{\beta}](\xi,\eta))(\tau) = (λ[ξ;ˉβ]0p(0,σ)η2(σ)dσ+λ[η;ˉβ]0p(0,σ)ξ2(σ)dσλ[ξ;ˉβ](η1+η2L1)λ[η;ˉβ](ξ1+ξ2L1)λ[ξ;ˉβ](τp(τ,σ)η2(σ)η2(τ))+λ[η;ˉβ](τp(τ,σ)ξ2(σ)ξ2(τ)))
    , $

    for $ \xi = {}^T(0, \xi_1, \xi_2(\cdot))\in Z_0 $ and $ \eta = {}^T(0, \eta_1, \eta_2(\cdot))\in Z_0 $. We define the linear operator $ \mathcal L : = D_u\mathcal G[0, 1] $. If $ \zeta \in \mathbb C $ is an eigenvalue of $ \mathcal L $, there exists $ \xi = {}^T(0, \xi_1, \xi_2(\cdot))\in Z_0\setminus \{ 0 \} $ such that

    $ ξ2(0)+qξ1=0,ζξ1=λ[ξ;1]N(μ+q)ξ1,ζξ2(τ)=ξ2(τ)(μ+γ(τ))ξ2(τ),
    $
    (6.6)

    Then the eigenvalue $ \zeta $ is given as a root of the characteristic equation:

    $ ζ+μ+q=β10+q0β20(τ)e(ζ+μ)τΓ(τ)dτ.
    $
    (6.7)

    If $ \bar{\beta} = 1 $, we can use the similar discussion as in the Section 4 to show that the equation (6.7) has a single solution zero and each of the remaining solutions has negative real part. Solving $ \mathcal L \xi = 0 $, the positive eigenvector $ \hat{v}_0 \in Z $ corresponding to the eigenvalue $ 0 $ is obtained as

    $ ˆv0=T(q,1,qeμτΓ(τ)).
    $
    (6.8)

    Next we calculate the adjoint operator of $ \mathcal L $ and its eigenfunctional corresponding to the dominant eigenvalue zero. For $ \xi = (0, \xi_1, \xi_2(\cdot)) \in Z_0 $ and $ \psi = {}^T (\psi_2(0), \psi_1, \psi_2(\cdot)) \in Z^* = \mathbb R \times \mathbb R \times L^\infty $,

    $ Lξ,ψ=(ξ2(0)+qξ1)ψ3+(λ[ξ,1]N(μ+q)ξ1)ψ10(ξ2(τ)+(μ+γ(τ))ξ2(τ))ψ2(τ)dτ=(ψ2(0)ψ3)ξ2(0)+(qψ3(μ+qβ10)ψ1)ξ1+0[ψ2(τ)(μ+γ(τ))ψ2(τ)+β20(τ)ψ1]ξ2(τ)dτ,
    $

    hence the following representation is obtained:

    $ Lψ(τ)=(ψ2(0)ψ3qψ3(μ+qβ10)ψ1ψ2(τ)(μ+γ(τ))ψ2(τ)+β20(τ)ψ1) for ψ(τ)=(ψ3ψ1ψ2(τ))Z,
    $
    (6.9)

    where $ Z^* $ denotes the adjoint space of $ Z $. In order to find the eigenvector of $ \mathcal L^* $ corresponding to the eigenvalue zero, we consider $ \mathcal L^* \psi = 0 $, that is,

    $ ψ2(0)=ψ3,(μ+qβ10)ψ=qψ3,ψ2(τ)=(μ+γ(τ))ψ2(τ)β20(τ)ψ1.
    $
    (6.10)

    By our assumption (6.3), we have

    $ μ+qβ10=q0β20(τ)eμσΓ(σ)dσ>0.
    $
    (6.11)

    Then it follows that

    $ ψ1=qψ3μ+qβ10.
    $
    (6.12)

    Solving the ordinary differential equation in (6.10), we have

    $ ψ2(τ)=ψ3eμτΓ(τ)qψ3μ+qβ10τ0β20(τ)eμ(στ)Γ(σ)Γ(τ)dσ=ψ3eμτΓ(τ)[1qμ+qβ10τ0β20(σ)eμσΓ(σ)dσ]=qψ3μ+qβ10τβ20(σ)eμ(στ)Γ(σ)Γ(τ)dσ.
    $
    (6.13)

    Therefore the unique (up to constant) eigenfunctional $ \hat{v}_0^* \in Z^* $ of $ \mathcal L^* $ corresponding to eigenvalue zero is obtained as

    $ ˆv0=(μ+qβ10q1τβ20(σ)eμ(στ)Γ(σ)Γ(τ)dσ).
    $
    (6.14)

    From the above, it is obvious that $ b : = \langle D^2_{u \bar{\beta}} \mathcal G[0, 1] (\hat v_0, 1), \hat v_0^* \rangle > 0 $, hence the bifurcation is backward if $ a > 0 $, while if $ a < 0 $, the bifurcation is forward.

    Now calculate the value of $ a: = \langle D^2_{uu} \mathcal G[0, 1](\hat v_0, \hat v_0), \hat v^*_0 \rangle $. Since

    $ D2uuG[0,1](ˆv0,ˆv0)=2λ[ˆv0;1](0p(0,η)qeμηΓ(η)dη(1+0qeμτΓ(τ)dτ)τp(τ,η)qeμηΓ(η)dηqeμτΓ(τ)),
    $
    (6.15)

    it follows that the value of $ a $ satisfies

    $ a=2(μ+q)N[μ+qβ10q0p(0,η)qeμηΓ(η)dη(1+0qeμτΓ(τ)dτ)+0σβ20(τ)eμ(τσ)Γ(τ)Γ(σ)dτ[σp(σ,η)qeμηΓ(η)dηqeμσΓ(σ)]dσ].
    $
    (6.16)

    In order to see the meaning of the bifurcation condition by the parameter $ a $, we adopt a more intuitive argument to find the direction of the bifurcation based on the characteristic equation (5.12). The direction of the bifurcation is determined by the sign of $ H'(0) $ when $ R_0 = 1 $. In fact, if $ R_0 < 1 $ but $ |R_0-1| $ is small enough, $ H'(0) > 0 $ implies the existence of positive solution for the equation (5.12) (Figure 1).

    Figure 1.  If $ H(0) < 1 $ and $ |H(0)-1| $ is sufficiently small, then there exist solutions for the equation $ H(\lambda^*) = 1 $.

    Then we can conclude that if $ H'(0) > 0 $, the bifurcation is backward, while it is forward if $ H'(0) < 0 $ at $ R_0 = 1 $. Now we prove the equivalence of both conditions.

    Proposition 6. Suppose that $ R_0 = 1 $. Then it holds that $ {\rm sign}(a) = {\rm sign}(H'(0)) $.

    Proof. First we calculate the derivative

    $ \left. \frac{d}{d\lambda^*}\frac{r^*(\tau)}{\lambda^*} \right|_{\lambda^* = 0} $

    using the equality (5.11). For the purpose of calculating the derivative at zero, we may neglect the second or higher terms of $ \lambda^* $, hence

    $ \left. \frac{d}{d\lambda^*}\frac{r^*(\tau)}{\lambda^*} \right|_{\lambda^* = 0} = \left. \frac{d}{d\lambda^*} \left( \frac{f_{\lambda^*}(\tau)}{\lambda^*} + \frac{V_\lambda^* f_{\lambda^*}}{\lambda^*}(\tau) + \frac{F_\lambda^* f_{\lambda^*}}{\lambda^*}(\tau) \right) \right|_{\lambda^* = 0}. $

    Since

    $ \left. \frac{d}{d\lambda^*}g(\tau;\lambda^*) \right|_{\lambda^* = 0} = -\tau e^{-\mu\tau}\Gamma(\tau) +e^{-\mu\tau}\Gamma(\tau) \int_0^\infty p(0,\eta) e^{-\mu\eta}\Gamma(\eta)d\eta $

    holds, it follows that

    $ \left. \frac{d}{d\lambda^*}\frac{f_{\lambda^*}(\tau)}{\lambda^*} \right|_{\lambda^* = 0} = \frac{qN}{\mu+q}e^{-\mu\tau}\Gamma(\tau) \left[ -\tau -\frac{1}{\mu} + \int_0^\infty p(0,\eta) e^{-\mu\eta}\Gamma(\eta)d\eta \right]. $

    Next,

    $ ddλVλfλλ(τ)|λ=0=0σp(σ,η)f(τ;λ)λ|λ=0ddλL(σ,τ;λ)|λ=0dηdσ=qNμ+qeμτΓ(τ)τ0σp(σ,η)eμ(ησ)Γ(η)Γ(σ)dηdσ
    $

    and

    $ ddλFλfλλ(τ)|λ=0=0qμ+qμNμ+λg(ζ;λ)g(τ;λ)(1μ+λqμ+qγ(ζ)+ζ0σp(σ,ζ)p(0,η)L(σ,η;λ)dηdσ)|λ=0dζ=eμτΓ(τ)Nμ(qμ+q)20eμηΓ(η)γ(η)dη
    $

    are obtained. Finally we arrive at the following expression:

    $ H(0)=β10μ(μ+q)+β10μ(μ+q)qμ+q0γ(τ)eμτΓ(τ)dτ+qμ+q0β20(τ)eμτΓ(τ)[τ1μ+0p(0,η)eμηΓ(η)dη+τ0σp(σ,η)eμ(ησ)Γ(η)Γ(σ)dηdσ+qμ(μ+q)0eμηΓ(η)γ(η)dη]dτ.
    $
    (6.17)

    Now let us prove that

    $ (μ+q)H(0)=N2(μ+q)a.
    $
    (6.18)

    Let

    $ (\mu+q)H^\prime(0) = H_1+H_2+H_3+H_4, $

    where

    $ H1:=β10μ+β10μqμ+q0eμτΓ(τ)γ(τ)dτqμ0β20(τ)eμτΓ(τ)dτ,H2:=q0β20(τ)eμτΓ(τ)dτ[0p(0,η)eμηΓ(η)dη+qμ(μ+q)0eμηΓ(η)γ(η)dη],H3:=q0β20(τ)eμτΓ(τ)τ0σp(σ,η)eμ(ημ)Γ(η)Γ(σ)dηdσdτ,H4:=q0τβ20(τ)eμτΓ(τ)dτ.
    $

    Note that the following holds:

    $ 0eμτΓ(τ)γ(τ)dτ=1μ0eμτΓ(τ)dτ.
    $
    (6.19)

    Then each $ H_i $ can be calculated as follows:

    $ H1=β10μ+q(1+q0eμτΓ(τ))qμ0β20(τ)eμτΓ(τ)dτ=(1qμ+q0β20(τ)Γ(τ)dτ)(1+q0eμτΓ(τ))qμ0β20(τ)eμτΓ(τ)dτ=(1+q0eμτΓ(τ))q2μ(μ+q)0β20(τ)eμτΓ(τ)dτ+q2μ+q0β20(τ)eμτΓ(τ)dτ0eμτΓ(τ)dτ,H2=q0β20(τ)eμτΓ(τ)dτ[0eμηΓ(η)(1η0p(σ,η)dη)dη+qμ(μ+q)(1μ0eμηΓ(η)dη)]=q2μ(μ+q)0β20(τ)eμτΓ(τ)dτq0β20(τ)eμτΓ(τ)dτ0η0p(σ,η)dσeμηΓ(η)dη+μqμ+q0β20(τ)eμτΓ(τ)dτ0eμηΓ(η)dη,H3=q0σσβ20(τ)eμτΓ(τ)p(σ,η)eμ(ησ)Γ(η)Γ(σ)dηdτdσ=0σβ20(τ)eμ(τσ)Γ(τ)Γ(σ)dτσqp(σ,η)eμηΓ(η)dηdσ,H4=0τ0dσβ20(τ)qeμτΓ(τ)dτ=0σβ20(τ)eμ(τσ)Γ(τ)Γ(σ)dτqeμσΓ(σ)dσ.
    $

    Therefore we have

    $ H(0)=0β20(τ)eμτΓ(τ)dτ0qeμηΓ(η)[1η0p(σ,η)dσ]dη(1+q0eμτΓ(τ))+0σβ20(τ)eμ(τσ)Γ(τ)Γ(σ)dτ[σqp(σ,η)eμηΓ(η)dηqeμσΓ(σ)]dσ=μ+qβ10q0p(0,η)qeμηΓ(η)dη(1+q0eμτΓ(τ))+0σβ20(τ)eμ(τσ)Γ(τ)Γ(σ)dτ[σp(σ,η)qeμηΓ(η)dηqeμσΓ(σ)]dσ,
    $
    (6.20)

    which implies the equality (6.18).

    In order to see under what kind of biological conditions the backward bifurcation could occur, let us define a function:

    $ F(η):=0β20(x+η)eμxΓ(x+η)Γ(η)dx.
    $
    (6.21)

    Then $ F(\eta) $ is the expected number of reproduction (reproductive value) for sub-clinically infected individuals at recovery-age $ \eta $, especially $ F(0) $ gives the reproduction number of newly recovered individuals. Note that our condition (6.3) is expressed as

    $ R0=β10μ+q+qμ+qF(0)=1.
    $
    (6.22)

    Moreover we define

    $ G(η):=F(0)p(0,η)+η0F(σ)p(σ,η)dσ.
    $
    (6.23)

    Then $ G(\eta) $ denotes the average reproduction number of sub-clinical individuals boosted at recovery-age $ \eta $.

    Proposition 7. Under the assumption $(6.3)$, backward bifurcation of endemic steady states occurs at $ R_0 = 1 $ from the disease-free steady state if and only if

    $ q0G(η)eμηΓ(η)dη>q0(F(η)+1)eμηΓ(η)dη+1.
    $
    (6.24)

    Proof. From the above arguments so far, it is sufficient to show that

    $ H(0)=q0G(η)eμηΓ(η)dηq0(F(η)+1)eμηΓ(η)dη1.
    $
    (6.25)

    It follows from (6.20) that

    $ H'(0) = qJ - 1 -q \int_0^\infty (1+F(\eta)) e^{-\mu\eta} \Gamma(\eta)d\eta, $

    where

    $ J:=0β20(τ)eμτΓ(τ)dτ0eμηΓ(η)(1η0p(σ,η)dσ)dη+0σβ20(τ)eμ(τσ)Γ(τ)Γ(σ)dτσp(σ,η)eμηΓ(η)dη=F(0)0eμηΓ(η)(1η0p(σ,η)dσ)dη+0F(σ)σp(σ,η)eμηΓ(η)dηdσ=0F(0)p(0,η)eμηΓ(η)dη+0η0F(σ)p(σ,η)dσeμηΓ(η)dη.
    $

    Therefore it is easy to see that (6.25) holds.

    Corollary 2. Suppose that

    $ G(η)F(η)+1,η0.
    $
    (6.26)

    Then the forward bifurcation of endemic steady states occurs at $ R_0 = 1 $ from the disease-free steady state. Especially one of the following typical conditions is satisfied, then (6.26) holds:

    1. $ F $ is constant,

    2. $ \sup_{\sigma \ge 0}F(\sigma) \le 1 $,

    3. $ p(0, \eta) = 1 $ and $ F(0) \le 1+F(\eta) $ for all $ \eta $.

    Proof. From (6.25), it is clear that (6.26) is a sufficient condition in order to satisfy $ H'(0) < 0 $. If $ F $ is constant, it follows from (2.4) that $ G(\eta)-F(\eta) = 0 $, hence we have (6.26). Next, from (2.4), we have $ G(\eta) \le \sup_{\sigma \ge 0}F(\sigma) $, so (6.26) holds if $ \sup_{\sigma \ge 0}F(\sigma) \le 1 $. Finally, if $ p(0, \eta) = 1 $ for all $ \eta $, that is, all newly reinfected individual has recovery age zero, it follows that $ G(\eta) = F(0) $, so again (6.26) holds, if $ F(0) \le 1+F(\eta) $ for all $ \eta $.

    Corollary 3. Suppose that $ \int_\sigma^\infty p(\sigma, \eta) d\eta \leq 1 $ for all $ \sigma > 0 $. Then, the endemic steady state bifurcates forwardly from the disease-free steady state at $ R_0 = 1 $.

    Proof. Since

    $ R_0 = \frac{\beta_{10}}{\mu+q} + \frac{q}{\mu+q}F(0) = 1, $

    we have $ \beta_{10} = \mu+q -q F(0) $. Since $ \beta_{10} $ is nonnegative, $ F(0) $ should satisfy

    $ F(0)μ+qq.
    $
    (6.27)

    Moreover, since $ p(0, \eta) = 1 - \int_0^\eta p (\sigma, \eta) d\sigma $ for all $ \eta > 0 $, we have

    $ p(0,η)1
    $
    (6.28)

    for all $ \eta > 0 $. From (6.27) and (6.28), we have

    $ q0F(0)p(0,η)eμηΓ(η)dη(μ+q)0eμηΓ(η)dημ0eμηdη+q0eμηΓ(η)dη=q0eμηΓ(η)dη+1.
    $
    (6.29)

    Moreover, we have

    $ q0η0F(σ)p(σ,η)dσeμηΓ(η)dη=q0F(σ)σp(σ,η)eμηΓ(η)dηdσ=q0F(σ){[ησp(σ,ρ)dρeμηΓ(η)]σ+σ[μ+γ(η)]ησp(σ,ρ)dρeμηΓ(η)dη}dσq0F(σ)σ[μ+γ(η)]eμηΓ(η)dηdσ=q0F(η)eμηΓ(η)dη.
    $
    (6.30)

    Since

    $ G(\eta) = F(0)p(0,\eta) + \int_0^\eta F(\sigma) p (\sigma,\eta) d\sigma, $

    we have from (6.29) and (6.30) that

    $ q \int_0^\infty G(\eta) e^{-\mu \eta} \Gamma(\eta) d\eta \leq q \int_0^\infty \left[ F(\eta) + 1 \right] e^{-\mu \eta} \Gamma(\eta) d\eta + 1. $

    Thus, the inequality (6.24) does not hold.

    Corollary 4. Suppose that $ F $ is monotone on $ [0, \infty) $. Then, the endemic steady state bifurcates forwardly from the disease-free steady state at $ R_0 = 1 $.

    Proof. First, suppose that $ F $ is monotone nonincreasing on $ [0, \infty) $. Since $ p(0, \eta) = 1-\int_0^\eta p(\sigma, \eta) d\sigma $ for all $ \eta > 0 $, we have

    $ G(η)=F(0)p(0,η)+η0F(σ)p(σ,η)dσ=F(0)+η0[F(σ)F(0)]p(σ,η)dσF(0)μ+qq,η0.
    $

    Hence, we have

    $ q0G(η)eμηΓ(η)dη(μ+q)0eμηΓ(η)dηq0eμηΓ(η)dη+μ0eμηdηq0[F(η)+1]eμηΓ(η)dη+1.
    $

    Thus, the inequality (6.24) in Proposition 7 does not hold. Next, suppose that $ F $ is monotone nondecreasing on $ [0, \infty) $. We then have

    $ G(η)=F(0)p(0,η)+η0F(σ)p(σ,η)dσF(0)p(0,η)+F(η)η0p(σ,η)dσF(0)+F(η)μ+qq+F(η),η0.
    $

    Hence, we have

    $ q0G(η)eμηΓ(η)dη(μ+q)0eμηΓ(η)dη+q0F(η)eμηΓ(η)dηq0[F(η)+1]eμηΓ(η)dη+μ0eμηdηq0[F(η)+1]eμηΓ(η)dη+1.
    $

    Thus, (6.24) in Proposition 7 does not hold.

    Proposition 8. $ F(0) \le1 $ if and only if

    $ 0β20(τ)eβ1τΓ(τ)dτ1.
    $
    (6.31)

    And the condition $(6.31)$ is satisfied if $ \sup_{\tau \ge 0}\beta_{20}(\tau) \le \beta_{10} $. Then if $ p(0, \eta) = 1 $ for all $ \eta \ge 0 $, the condition $(6.31)$ is a sufficient condition to show that the forward bifurcation of endemic steady states occurs at $ R_0 = 1 $ from the disease-free steady state.

    Proof. It follows from (6.22) that $ \beta_{10}-\mu = q(1-F(0)) $. Then $ F(0) \le 1 $ implies $ \beta_{10} \ge \mu $. Hence we have

    $ \int_0^\infty \beta_{20}(\tau)e^{-\beta_{10} \tau}\Gamma(\tau)d\tau \le \int_0^\infty \beta_{20}(\tau)e^{-\mu \tau}\Gamma(\tau)d\tau = F(0) \le 1, $

    so $ F(0) \le 1 $ implies (6.31). Conversely suppose that (6.31) holds. If we assume that $ F(0) > 1 $, it follows that $ \beta_{10}-\mu < 0 $, which implies

    $ F(0) < \int_0^\infty \beta_{20}(\tau)e^{-\beta_1 \tau}\Gamma(\tau)d\tau \le 1, $

    which contradicts $ F(0) > 1 $, then it must hold that $ F(0) \le 1 $. Therefore, the condition (6.31) implies $ F(0) \le 1 $, and it also implies the condition 3 of Corollary 2, so the bifurcation is forward. Finally note that if $ \sup_{\tau \ge 0}\beta_{20}(\tau) \le \beta_{10} $, then we can observe that

    $ \int_0^\infty \beta_{20}(\tau)e^{-\beta_{10} \tau}\Gamma(\tau)d\tau \le \frac{\sup\limits_{\tau \ge 0}\beta_{20}(\tau)}{\beta_{10}} \le1. $

    Then the condition (6.31) is satisfied.

    From the above propositions, we know that age-dependent variability of the transmission coefficient for subclinical status is needed to produce possibility of backward bifurcation of endemic steady states at $ R_0 = 1 $ from the disease-free steady state. Yang and Nakata [32] proved that if $ p(0, \eta) = 1 $ for all $ \eta \ge 0 $ and the condition (6.31) is satisfied, there exists a unique endemic steady state exists if and only if $ R_0 > 1 $. Therefore, if all newly boosted infecteds have the recovery-age zero, subcritical endemic steady state does not exist if there is no enhancement of the infectivity such that $ \sup_{\tau \ge 0}\beta_{20}(\tau) > \beta_{10} $ among subclinical infecteds.

    In this paper, we have extended the Aron epidemic model so that the immunity clock can be reset to any time less than the recovery-age at which reinfection occurs. If we assume that the immunity level is determined by the immunity clock, our model assumption allows that newly boosted (reinfected) individuals could get any level of immunity, which is a most flexible extension for the epidemic with boosting and waning of immune status.

    We have established the mathematical well-posedness of our formulation and have shown that the initial invasion condition and the endemicity can be characterized by the basic reproduction number $ R_0 $. Our focus is the bifurcation analysis of endemic steady states. Based on Lyapunov–Schmidt type arguments, we have determined the direction of bifurcation that endemic steady states bifurcate from the disease-free steady state when the basic reproduction number passes through the unity. We have given a necessary and sufficient condition for backward bifurcation to occur. Although we have not yet discovered biologically reasonable, concrete numerical examples of subcritical endemic steady states for our model*, we have cleared what kind of mathematical conditions are needed to create the backward bifurcation from the disease-free steady state under the reset mechanism of the immunity clock.

    *In numerical simulation, we can use a standard method such as Gauss-Laguerre quadrature to calculate numerical integrals on infinite intervals.

    Mathematically speaking, even in case that the forward bifurcation occurs, it is still a difficult problem to show conditions for the uniqueness of endemic steady state. It is a future challenge to investigate the global dynamics of the epidemic model with boosting and waning of immune status. From application point of view, it would be also important to extend our recovery-age dependent model to take into account the chronological-age structure of host population. As is suggested in [4], the chronological-age dependent model is essential to understand the age-specific prevalence dynamics for the epidemic with boosting and waning of immune status.

    Finally, we can again stress importance to consider the waning and boosting dynamics in the real-world application. As is strongly expected in the pandemic of COVID-19, we believe that vaccination is the most effective tool to control the pandemic. However, if the effect of vaccination is not necessarily lifelong and it will wane as time evolves, so we may well have to boost the immune status by repeating vaccination to keep the herd immunity. To make an appropriate immunization policy, we may need to know the waning and boosting dynamics of immune status under any vaccination policy. It is a future challenge to extend our model by taking into account possible vaccination policy.

    Kento Okuwa and Hisashi Inaba are supported by the Japan Society for the Promotion of Science (JSPS), Grant-in-Aid for Scientific Research (C) (No.16K05266). Toshikazu Kuniya is supported by JSPS Grant-in-Aid for Early-Career Scientists (No.19K14594).

    There is no conflict of interest.

    [1] Phil Hogan EU Commissioner for Agriculture (2015) Interview at the Forum for the Future of Agriculture by Views.eu, [online]. While using this quote EPHA however disagrees that the CAP should not be about farmers.
    [2] Tim Lang (2004) European agricultural policy: Is health the missing link? In: London School of Economics and Political Science, Eurohealth issue: Integrating Public Health with European food and agricultural policy. online. Of course the policy also aimed to provide economic security for the farming population, which is visible in the CAP's mission statement.
    [3] Also, in the past nutrient recommendation for protein intake, especially animal protein, was around twice as high as it is today, see for instance: J. Périssé (1981) Joint FAO/WHO/UNU Expert Consultation on Energy and Protein Requirements [online].
    [4] WHO Europe (2015) European Health Report 2015. [online]
    [5] Art 168 Treaty on the Functioning of the European Union (TFEU). [online]
    [6] WHO Europe (2012) Action plan for implementation of the European strategy for the Prevention and Control of Noncommunicable Diseases 2012-2016, p. 5. [online]
    [7] Outcome of the “Global Burden of Disease” study (2013), a collaboration between seven leading international scientific institutes to systematically quantify the main causes of health loss. Institute for Health Metrics and Evaluation. University of Washington (2013) The global burden of disease. Generating evidence, guiding policy. European Union and European Free Trade Association Regional Edition. [online]
    [8] The Disability Adjusted Life Year (DALY) is a measure of overall disease burden expressed as the number of years lost due to ill-health, disability or early death. The measure combines mortality and disease into one indicator.
    [9] European Commission. Infographic: Tobacco in the EU. [online]
    [10] FAO (2012) Sustainable diets and biodiversity. Directions and solutions for policy research and action. Proceedings of International Scientific Symposium. [online]
    [11] Tim Lang et al. (2012) Ecological public health: the 21st century's big idea? The BMJ. [online]
    [12] Lancet Commission on planetary health (2015) Safeguarding human health in the Anthropocene epoch. The Lancet. [online]
    [13] Nick Watts et al. (2015) Health and climate change: policy responses to protect public health. The Lancet. [online]
    [14] National Nutrition Council of Finland (2014) Finnish Nutrition Recommendations 2014. [online]
    [15] Global Meat News (2015) Latest US dietary advice to avoid limiting meat. [online]
    [16] European Commission (2013) Overview of CAP Reform 2014-2020. [online]
    [17] OECD (2015) Focus on Health Spending. Health Statistics 2015. [online]
    [18] OECD iLibrary, Health at a Glance: Europe 2012. [online]
    [19] Vytenis Andriukaitis (16 July 2015) Speech outlining priorities for health until 2019 at European Policy Centre, [online]
    [20] Sophie Hawkesworth et al. (2010) Feeding the world healthily: the challenge of measuring the effects of agriculture on health. Philosophical Transactions B of The Royal Society. [online]
    [21] Schäfer Elinder (2003) Public health aspects of the EU Common Agricultural Policy. Developments and recommendations for change in four sectors: Fruit and vegetables, dairy, wine and tobacco. National Institute of Public Health, Sweden
    [22] Christopher Birt et al. (2007) A CAP on Health? The impact of the EU Common Agricultural Policy on public health. Faculty of Public Health. [online]
    [23] Boyd Swinburn et al. (2011) The global obesity pandemic: shaped by global drivers and local environments. The Lancet. [online]
    [24] Stefanie Vandevijvere et al. (2015) Increased food energy supply as a major driver of the obesity epidemic: a global perspective. Bulletin of the World Health Organisation. [online]
    [25] Boyd Swinburn et al. (2009) Increased food energy supply is more than sufficient to explain the US epidemic of obesity. Am J Clin Nutr. [online]
    [26] P. Scarborough et al. (2011) Increased energy intake entirely accounts for increase in body weight in women but not in men in the UK between 1968 and 2000. Br J Nutr. [online]
    [27] T. Rawe et al. (2015) Cultivating equality: delivering just and sustainable food systems in a changing climate. CGIAR. [online]
    [28] Josef Schmidhuber (2007) The EU Diet - Evolution, Evaluation and Impacts of the CAP. FAO. [online]
    [29] Ralf Peters (2006) Roadblock to reform: the persistence of agricultural export subsidies. UNCTAD. [online]
    [30] Eurostat. Cross-country comparison of final consumption expenditures on food and housing in 2011. [online]
    [31] Franco Sassi (2010) Obesity and the Economics of Prevention - Fit not fat. OECD. [online]
    [32] D. Lakdawalla et al. (2002) The Growth of Obesity and Technological Change: A theoretical and Empirical Examination. National Bureau for Economic Research. Working Paper W8946. [online]
    [33] Alan Matthews (2015) Forum for the Future of Agriculture 2015 - Remarks on EU agricultural trade policy. CAPreform.eu. [online]
    [34] Corinna Hawkes et al. (2012) Linking agricultureal policies with obesity and noncommunicable diseases: A new perspective for a globalising world. Food Policy. [online]
    [35] A similar case was made by: The Netherlands Scientific Council for Government Policy (2014) Towards a food policy. English synopsis. [online]
    [36] WHO Europe (2000) The First Action Plan for Food and Nutrition Policy (2000-2005). [online]
    [37] EPHA (2010) Response to the “The Future of the Common Agricultural Policy” consultation. online. European Public Health & Agriculture Consortium (2011) Response to the “Reform of the CAP towards 2020 - impact assessment”. [online]
    [38] Olivier de Schutter (2014) Report of the Special Rapporteur on the right to food, Final report: The transformative potential of the right to food. UN. [online]
    [39] Regulation (EU) No 1307/2013 establishing rules for direct payments to farmers under support schemes within the framework of the common agricultural policy. [online]
    [40] Regulation (EU) No 1308/2013 establishing a common organisation of the markets in agricultural products. [online]
    [41] Regulation (EU) No 1305/2013 on support for rural development. [online]
    [42] Treaty on the European Union. online. Treaty on the Functioning of the European Union. [online]
    [43] Karen Lock et al. (2003) Health impact assessment of agriculture and food policies: lessons learnt from the Republic of Slovenia. Bulletin of the World Health Organisation. [online]
    [44] Vytenis Andriukaitis. EU Commissioner for Health (2015) Letter to the EU Ministers of Health. [online]
    [45] Scotch Whisky Association, the European Spirits Association and the Comité Européen des Entreprises Vins.
    [46] Scottish Court of Session (2013) Opinion by Lord Doherty. online. Judiciary of Scotland (2013) Petition for Judicial Review by Scotch Whisky Association & Others, [online]
    [47] Politico (2015) Health chief blasts alcohol lobbyists. [online]
    [48] Case C-333/14: Reference for a preliminary ruling from Court of Session, Scotland (United Kingdom) made on 8 July 2014 — The Scotch Whisky Association and others against The Lord Advocate, The Advocate General for Scotland. [online]
    [49] Opinion of Advocate General Yves Bot (2015) In the case: The Scotch Whisky Association and others against The Lord Advocate, The Advocate General for Scotland. [online]
    [50] WHO (2014) Global Status Report on Alcohol and Health 2014. [online]
    [51] OECD (2015) Tackling harmful alcohol use. online. OECD (2015) Policy Brief. Tackling harmful alcohol use, [online]
    [52] Giulia Meloni et al. (2012) The Political Economy of European Wine Regulation. Centre for Institutions and Economic Performance. Catholic University of Leuven. [online]
    [53] European Commission (2006) Towards a sustainable European wine sector. [online]
    [54] European Court of Auditors (2014) Is the EU investment and promotion support to the wine sector well managed and are its results on the competitiveness of EU wines demonstrated?. [online]
    [55] European Court of Auditors (2012) The reform of the common organisation of the market in wine: progress to date. [online]
    [56] Article 63 CMO Regulation. Member States may also choose to authorise less, but it may not be 0% or lower.
    [57] European Court of Auditors (2014) Is the EU investment and promotion support to the wine sector well managed and are its results on the competitiveness of EU wines demonstrated? [online]
    [58] Article 39 CMO Regulation
    [59] Articles 45 to 52 of the CMO Regulation
    [60] Article 44 CMO Regulation referring to Annex VI
    [61] European Commission (2013) Wine CMO: First submission of financial table of the national support programme. [online]. Submissions were made under the previous CMO for wine, reviewed national envelopes are forthcoming.
    [62] Article 45 CMO Regulation
    [63] European Court of Auditors (2014) Is the EU investment and promotion support to the wine sector well managed and are its results on the competitiveness of EU wines demonstrated? [online]
    [64] Articles 50 and 51 CMO Regulation
    [65] European Court of Auditors (2014) Is the EU investment and promotion support to the wine sector well managed and are its results on the competitiveness of EU wines demonstrated? [online]
    [66] Articles 48 and 49 CMO Regulation
    [67] Articles 47 CMO Regulation
    [68] Articles 52 CMO Regulation
    [69] For more on the effects of the previous distillation support regimes: Schäfer Elinder (2003) Public health aspects of the EU Common Agricultural Policy. Developments and recommendations for change in four sectors: Fruit and vegetables, dairy, wine and tobacco. National Institute of Public Health, Sweden.
    [70] European Commission (2002) Ex-post evaluation of the CMO for wine, Chapter 5. Distillation. [online]
    [71] Article 46 CMO Regulation
    [72] European Court of Auditors (2012) The reform of the common organisation of the market in wine: progress to date. [online]
    [73] Giulia Meloni et al. (2015) L'Histoire se repete. Why the liberalization of the EU vineyard planting rights regime may require another French Revolution. Centre for Institutions and Economic Performance. Catholic University of Leuven. [online]
    [74] European Court of Auditors (2012) The reform of the common organisation of the market in wine: progress to date. [online]
    [75] Giulia Meloni et al. (2015) L'Histoire se repete. Why the liberalization of the EU vineyard planting rights regime may require another French Revolution. Centre for Institutions and Economic Performance. Catholic University of Leuven. [online]
    [76] Nick Sheron, University of Southampton, unpublished graph. Values are measured in Purchasing Power Standard (PPS) based on data provided by DG AGRI, Eurostat and the WHO HFA database and analysed in SPSS(48, 78).
    [77] The Brewers of Europe (2014) Beer Statistics 2014 edition. [online]WHO (2014) Global Status Report on Alcohol and Health 2014. [online]
    [78] European Commission. DG Agriculture and Rural Development. Hops. [online]
    [79] Deloitte, LEI Wageningen, Arcadia International (2009) Evaluation of the CAP measures relating to hops. [online]
    [80] Article 52 Direct Payments Regulation
    [81] European Commission. Infographic: Tobacco in the EU. online. In the past tobacco was also quite widely used in medicinal applications. See: Anne Charlton (2004) Medicinal uses of tobacco in history, Journal of the Royal Society of Medicine, [online].
    [82] Anna Gilmore et al. (2004) Tobacco-control policy in the European Union in: Eric Feldman et al. (ed) (2004) Unfiltered: Conflicts Over Tobacco Policy and Public Health. Harvard University Press.
    [83] European Court of Auditors (1987) Special Report No 3/87. The common organisation of the market in raw tobacco accompanied by the Commission's replies. [online]
    [84] Luk Joossens et al. (1996) Are tobacco subsidies a misuse of public funds? BMJ. [online]
    [85] Anna Gilmore et al. (2004) Tobacco-control policy in the European Union in: Eric Feldman et al. (ed) (2004) Unfiltered: Conflicts Over Tobacco Policy and Public Health. Harvard University Press.
    [86] Joy Townsend (1991) Tobacco and the European common agricultural policy. BMJ Clinical Research. [online]
    [87] COGEA (2009) Evaluation of the CAP measures relating to the raw tobacco sector Synopsis. [online]
    [88] Article 52 Direct Payments Regulation
    [89] Under Article 68 of Council Regulation (EC) No 73/2009. The scheme runs until 2014. See: European Commission Answer to a written MEP question by Brian Hayes (E-005093-15). [online]
    [90] See discussion below under the section: “Towards forward-looking direct payments”.
    [91] As the principle of decoupled payments applies, it may no longer be possible to identify a tobacco farmer according to the documentation submitted to payment authorities. A separate question should therefore be included on whether the applicant cultivates tobacco. In case of fraud all granted support should be returned accompanied by an administrative penalty.
    [92] WHO (2015) WHO calls on countries to reduce sugars intake among adults and children. [online]
    [93] WHO (2015) Guideline: Sugars intake for adults and children. [online]
    [94] For instance cardiovascular disease: Q. Yang et.al. (2014) Added sugar intake and cardiovascular disease mortality among US adults. JAMA Intern Med. [online]
    [95] UCLA Newsroom (2012) This is your brain on sugar: UCLA study shows high-fructose diet sabotages learning, memory. [online]
    [96] Arthur Westover et.al. (2002) A cross-national relationship between sugar consumption and major depression? Depression and Anxiety. [online]
    [97] Emory Health Sciences (2014) High-fructose diet in adolescence may exacerbate depressive-like behaviour. Science Daily. [online]
    [98] European Commission (1978), Commission Communication Future development of the Common Agricultural Policy. [online]
    [99] Emilie Aguirre et al. (2015) Liberalising agricultural policy for sugar in Europe risks damaging public health. [online]
    [100] ""Allison Burell et al. (2014) EU sugar policy: A sweet transition after 2015? Joint Research Centre. online. Restructuring of the sugar sector in 2006 also lead to a strong centralisation of sugar production and processing with many factory closings in countries like Poland and Italy. Much of the sugar processing is now concentrated, which drops a shadow over regional and rural development objectives.
    [101] Article 124 and further and Article 232 CMO Regulation
    [102] European Commission (2014) Prospects for EU agricultural markets and income 2014-2024. [online]
    [103] Allison Burell et al. (2014) EU sugar policy: A sweet transition after 2015? Joint Research Centre. [online]
    [104] Alan Mathews (2014) EU beet sugar prices to fall by 22-23% when quotas eliminated. CAPreform.eu. [online]
    [105] C. Bonnet et al. (2011) Does the EU sugar policy reform increase added sugar consumption? An empirical evidence on the soft drink market. Health Economics. [online]
    [106] Roya Kelishadi, et al. (2014) Association of fructose consumption and components of metabolic syndrome in human studies: A systematic review and meta-analysis, Nutrition. [online]
    [107] Victoria Schoen et al. (2015) Should the UK be concerned about sugar? Food Research Collaboration. [online]
    [108] Kawther Hashem et al. (2015) Does sugar pass the environmental and social test? Food Research Collaboration [online]
    [109] Allison Burell et al. (2014) EU sugar policy: A sweet transition after 2015? Joint Research Centre. [online]
    [110] Article 52 Direct payments Regulation
    [111] European Commission (2014) The CAP towards 2020, Implementation of the new system of direct payments. MS notifications. [online]
    [112] WHO (2015) Healthy Diet. Fact sheet No 394. [online]
    [113] Henk Westhoek et al. (2011) The protein puzzle, the consumption and production of meat, dairy and fish in the European Union. Netherlands Environmental Assessment Agency. [online]
    [114] European Commission (2012) Consultation paper: options for resource efficiency indicators. [online]
    [115] International Agency for Research on Cancer (2015) Press release. IARC Monographs evaluate consumption of red meat and processed meat. online. Red meat includes beef, pork, lamb and mutton, goat
    [116] World Cancer Research Fund. Red and processed meat and cancer prevention. online. Referring to meats which are preserved through smoking, curing, salting or through addition of preservatives, including ham, salami, bacon, sausages, hot dogs etc.
    [117] World Cancer Research Fund, American Institute of Cancer Research (2007) Second Expert Report: Food, Nutrition, Physical activity and the Prevention of Cancer: a Global Perspective. [online]
    [118] Henk Westhoek et.al. (2014) Food choices, health and environment: Effects of cutting Europe's meat and dairy intake. Global Environmental Change. [online]
    [119] Mark Sutton et al. (ed) (2011) The European Nitrogen Assessment. Sources, effects and policy perspectives. [online]
    [120] European Commission (2004) The meat sector in the European Union. [online]
    [121] See for instance: World Resource Institute. Data series: Meat consumption per capita. [online]
    [122] European Commission (1980) Agriculture and the problem of surpluses. p. 18-19. [online]
    [123] Article 52 Direct payments Regulation
    [124] Article 53 Direct payments Regulation
    [125] 15% from all net ceilings added up. See Annex III Direct payments Regulation.
    [126] European Commission. EU Draft Budget for 2016. online. Budget lines starting from code 05.
    [127] Alan Mathews (2015) Two steps forward, one step back: coupled payments in the CAP. CAPreform.eu. [online]
    [128] European Commission (2014) The CAP towards 2020. Implementation of the new system of direct payments. MS notifications. [online]. Promoting protein crop production in Europe can however be considered positive as a way to replace soy import from South America.
    [129] European Court of Auditors (2012) Suckler cow and ewe and goat direct aids under partial implementation of SPS arrangements. online. Both these schemes expired in 2014 together with Regulation (EC) No 73/2009 on direct support schemes for farmers under the common agricultural policy.
    [130] Article 52(8) Direct payment Regulation
    [131] Article 26 CMO Regulation and further
    [132] European Parliament Procedure File 2014/0014 COD. Aid scheme for the supply of fruit and vegetables, bananas and milk in the educational establishments. online. See also: Text adopted in EP Plenary on 27 May. [online]
    [133] Eurostat (2011) Food: From farm to fork statistics. [online]
    [134] FAO. Milk and Dairy products in human nutrition - questions and answers. [online]
    [135] FAO. Food-based dietary guidelines, Food guidelines by country. online. . For criticism on reduced fat milk see for instance: David Ludwig et al. (2011) Three daily servings of reduced-fat milk - an evidence based recommendation? JAMA Pediatrics. [online]
    [136] Articles 11 and 16 CMO Regulation
    [137] Article 17 CMO Regulation
    [138] European Commission (2015) Private storage in the pig meat sector. [online]
    [139] European Commission Press release (2015) Safety net measures for dairy, fruit and vegetables to be extended. [online]
    [140] Article 196 CMO Regulation
    [141] Article 219 CMO Regulation. See also: Alan Mathews (2013) The end of export subsidies? CAPreform.eu. [online]
    [142] Article 220 CMO Regulation
    [143] European Parliament Resolution of 7 July 2015 on prospects for the EU dairy sector - review of the implementation of the Dairy Package online. See also: European Parliament News (2015) End of milk quotas: “Opportunities to build a more confident and robust dairy sector”. [online]
    [144] Euractiv (2014) Moscow pork embargo causes havoc in Brussels. [online]
    [145] AHDB Dairy (2015) EU Farmgate milk prices. [online]
    [146] Copa-Cogeca Press release (2015) Copa and Cogeca warn at EU Milk Market Observatory meeting market deteriorated rapidly in past 4 weeks and EU action crucial. online. See also: Euractiv (2015) France promises emergency aid to farmers, online. & Euractiv (2015), Farmers look to EU food aid to boost meat market. [online]
    [147] See for instance: VILT.be (2015) Landbouworganisaties komen met gemeeschappelijke eisen. online. A coalition of Belgian farmers' organizations demands what farmers really want i.e. fair prices.
    [148] Aileen Robertson et al. (ed) (2004) Food and health in Europe: a new basis for action. WHO Europe. [online]
    [149] M. Crawford et al. (1970) Comparative studies on fatty acid composition of wild and domestic meats. International Journal of Biochemistry. [online]
    [150] Compassion in World Farming (2012) Nutritional benefits of higher welfare animal products. [online]
    [151] B. H. Schwendel et al. (2014) Organic and conventionally produced milk - An evaluation of factors influencing milk quality. Journal of Dairy Science. [online]
    [152] Liesbet Smit et al. (2010) Conjugated linoleic acid in adipose tissue and risk of myocardial infarction. The American Journal of Clinical Nutrition. [online]
    [153] Compassion in World Farming, World Society for the Protection of Animals (2013) Zoonotic diseases, human health and farm animal welfare. [online]
    [154] WHO (2015) Healthy Diet. Fact sheet No 394. [online]
    [155] EUFIC (2012) Fruit and vegetables consumption in Europe - do Europeans get enough? [online]
    [156] European Association for the Fresh Fruit and Vegetables Sector (2015) Freshfel Consumption Monitor. [online]
    [157] AFC Management Consulting (2012) Evaluation of the European School Fruit Scheme - Final report. For the European Commission. [online]
    [158] WHO (2009) Global Health Risks Summary Tables. [online]
    [159] Article 23 CMO Regulation and further
    [160] European Parliament Procedure File 2014/0014 COD. Aid scheme for the supply of fruit and vegetables, bananas and milk in the educational establishments. online. See also: Text adopted in EP Plenary on 27 May. [online]
    [161] See for instance: Joint Open letter: Save the EU School Fruit Scheme: ‘Better Regulation' cannot go against the wellbeing of European children (2015). [online]
    [162] European Court of Auditors (2011) Are the School milk and School fruit schemes effective? [online]
    [163] AFC Management Consulting (2012) Evaluation of the European School Fruit Scheme - Final report. For the European Commission. [online]
    [164] Processed fruits and vegetables are allowed but without added sugar, added fat, added salt, added sweeteners and/or artificial flavour enhancers (artificial food additive codes E620-E650)
    [165] European Parliament Policy Study (2011) The EU Fruit and vegetables sector: overview and post-2013 CAP perspective. [online]
    [166] Article 32 CMO Regulation and further
    [167] European Commission. EU Draft Budget for 2016. online. Budget lines starting with code 05.
    [168] European Parliament Policy Study (2015) Towards new rules for the EU's fruit and vegetables sector. [online]
    [169] Schäfer Elinder (2003) Public health aspects of the EU Common Agricultural Policy. Developments and recommendations for change in four sectors: Fruit and vegetables, dairy, wine and tobacco. National Institute of Public Health, Sweden
    [170] Lennert Veerman et al. (2005) The European Common Agricultural Policy on fruits and vegetables: exploring potential health gain from reform. European Journal of Public Health. [online]
    [171] European Commission. Fruit and vegetables: crisis prevention and management. [online]
    [172] Steve Wiggins et al. (2015) The rising cost of a healthy diet - changing relative prices of food in high income and emerging economies. Overseas Development Institute, UK. [online]
    [173] European Parliament resolution of 7 July 2015 on the fruit and vegetables sector since the 2007 reform. [online]
    [174] Luciano Trentini (2015) Les fruits et légumes européens dans le monde. Fruit and Horticultural European Regions Assembly. [online]
    [175] Luciano Trentini (2015) Fruit and Horticultural European Regions Assembly. [online]
    [176] Jos Bijman (2015) Towards new rules for the EU's fruit and vegetables sector. European Parliament policy study. [online]
    [177] European Heart Network (2008) Response to “Towards a possible European school fruit scheme - Consultation document for impact assessment”. [online]
    [178] Karen Lock et al. (2005) Fruit and vegetable policy in the European Union: Its effects on the burden of cardiovascular disease. London School of Hygiene and Tropical Medicine, European Heart Network. [online]
    [179] European Parliament resolution of 7 July 2015 on the fruit and vegetables sector since the 2007 reform. [online]
    [180] An Ruopeng (2015) Nationwide Expansion of a Financial Incentive Program on Fruit and Vegetable Purchases among Supplemental Nutrition Assistance Program Participants: A Cost-effectiveness Analysis. Social Science & Medicine. [online]
    [181] F. Ford et al. (2009) Effect of the introduction of ‘Healthy start' on dietary behaviour during and after pregnancy: early results from the ‘before and after'. [online]
    [182] European Commission (2014) First Commission interim report on the implementation of Pilot Projects and Preparatory Actions 2014. [online]
    [183] Anne-Marie Mayer (1997) Historical changes in the mineral content of fruits and vegetables. British Food Journal. [online]
    [184] Aileen Robertson et al. (ed) (2004) Food and health in Europe: a new basis for action. WHO Europe. [online]
    [185] See: Directive 2009/128/EC establishing a framework for Community action to achieve the sustainable use of pesticides. [online]
    [186] European Commission (2015) Annex Promotion on the internal market and in third countries. online. See also: European Commission Press release (2015) The Commission approves new promotion programmes for agricultural products. [online]
    [187] European Commission (2014) Formal adoption of new EU promotion rules for agricultural products. [online]
    [188] European Commission (2015) The new promotion policy. Synoptic presentation. [online]
    [189] Regulation (EU) No 1144/2014 on information provision and promotion measures. [online]
    [190] Graph: European Commission (2013) Overview of CAP Reform 2014-2020. online. First pillar funding amount is in current prices.
    [191] European Commission DG AGRI (2011) The Future of CAP Direct Payments. [online]
    [192] Article 25 and further Direct Payments Regulation
    [193] European Parliament Policy Study (2015) Implementation of the First Pillar of the CAP 2014-2020 in the EU Member States. [online]
    [194] European Commission DG AGRI (2013) CAP reform - an explanation of the main elements. [online]
    [195] Article 36 Direct Payments Regulation
    [196] Article 21 Direct Payments Regulation
    [197] See for instance: Alan Mathews (2009) How decoupled is the single farm payment? CAPreform.eu. [online]
    [198] The Economist (2005) Europe's farm follies. [online]
    [199] European Parliament Policy Study (2015) Extent of Land Grabbing in the EU. [online]
    [200] Article 41 and further Direct payments Regulation
    [201] Article 61 and further Direct payments Regulation
    [202] Article 11 Direct payments Regulation
    [203] European Commission DG AGRI (2013) Structure and dynamics of EU farms: changes, trends and policy relevance. [online]
    [204] European Commission (2010) Does population decline lead to economic decline in EU rural regions? [online]
    [205] The Economist (2015) Rural France. Village croissant. [online]
    [206] WHO Europe (2012) Addressing the social determinants of health: the urban dimension and the role of local government [online]
    [207] John Bryden et al. (2004) Rural development and food policy in Europe. In: London School of Economics and Political Science. Eurohealth issue: Integrating Public Health with European food and agricultural policy. [online]
    [208] European Parliament Policy Study (2015) Towards new rules for the EU's fruit and vegetables sector. [online]
    [209] Article 5 Direct payments Regulation referring to Regulation (EU) online. which contains the list of cross-compliance measures in Annex II
    [210] European Council of the European Union. Simplification of the EU's Common Agricultural Policy (CAP). [online]
    [211] Article 43 and further Direct payments Regulation
    [212] Directive 2009/128/EC establishing a framework for Community action to achieve the sustainable use of pesticides
    [213] Recital 2 Rural development Regulation
    [214] European Commission (2013) Overview of CAP Reform 2014-2020. [online]. In current prices. Rural development measures, unlike direct payments or market measures, are co-financed by Member States.
    [215] Article 13 and further Rural development Regulation
    [216] Joris Aertsen et.al. (2013) Valuing the carbon sequestration potential for European agriculture. Land Use Policy. [online]
    [217] FAO (2013) Advancing agroforestry on the policy agenda. [online]
    [218] European Commission (2014) Investment support under Rural Development Policy. online. Implementation of the First Pillar of the CAP 2014-2020 in the EU Member States
    [219] European Court of Auditors (2014) Special report no 23/2014: Errors in rural development spending: what are the causes, and how are they being addressed? [online]
    [220] Article 14 Direct payments Regulation. See also: Wageningen University, IEEP (2009) Study on the impact of modulation. [online]
    [221] European Parliament Policy Study (2015) Implementation of the First Pillar of the CAP 2014-2020 in the EU Member States. [online]
    [222] FAO (2012) Sustainable diets and biodiversity. Directions and solutions for policy research and action. Proceedings of International Scientific Symposium. [online]
    [223] European Commission (2011) Evaluation of effects of direct support on farmers' incomes. [online]
    [224] Eurostat. Cross-country comparison of final consumption expenditures on food and housing in 2011. online. In UK and Luxembour the average is below 10%, while in Latvia and Estonia it is near 20% of total expenditure.
    [225] OECD (2012) Income inequality in the European Union. [online]
    [226] UCL Institute of Health Equity (2014) Review of social determinants and the health divide in the WHO European Region: final report. WHO Europe. [online]
    [227] Eurostat data in: Euractiv (2014) One out of four EU citizens at risk of poverty. [online]
    [228] Aileen Robertson et al. (2007) Obesity and socio-economic groups in Europe: Evidence review and implications for action. Report for European Commission. [online]
    [229] A. Drewnowski (2009) Obesity, diets and social inequality, Nutrition Reviews, online. See also: WHO (2012) Environmental Health Inequalities in Europe. [online]
    [230] Belinda Loring et al. (2014) Obesity and inequities Guidance for addressing inequities in overweight and obesity. [online]
    [231] European Commission (2005) The contribution of health to the economy in the European Union. [online]
    [232] Lancet Commission on planetary health (2015) Safeguarding human health in the Anthropocene epoch. The Lancet. [online]
  • This article has been cited by:

    1. Cyrille Kenne, Pascal Zongo, René Dorville, A mathematical model for tilapia lake virus transmission with waning immunity, 2022, 16, 1751-3758, 98, 10.1080/17513758.2022.2033860
    2. Cyrille Kenne, Gisèle Mophou, René Dorville, Pascal Zongo, A Model for Brucellosis Disease Incorporating Age of Infection and Waning Immunity, 2022, 10, 2227-7390, 670, 10.3390/math10040670
    3. Flavius Guiaş, Equilibrium Solutions of a Modified SIR Model with Vaccination and Several Levels of Immunity, 2023, 18, 2224-2856, 550, 10.37394/23203.2023.18.57
    4. Nursanti Anggriani, Lazarus Kalvein Beay, Meksianis Z. Ndii, Fatuh Inayaturohmat, Sanubari Tansah Tresna, A mathematical model for a disease outbreak considering waning-immunity class with nonlinear incidence and recovery rates, 2024, 6, 25889338, 170, 10.1016/j.jobb.2024.05.005
    5. Liming Cai, Mingrui Lei, Jin Wang, Backward Bifurcation of an Age-Structured Epidemic Model with Partial Immunity, 2025, 35, 0218-1274, 10.1142/S0218127425500956
  • Reader Comments
  • © 2015 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(12320) PDF downloads(1207) Cited by(3)

Figures and Tables

Figures(10)

Other Articles By Authors

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog